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Overview:
Globalization of innovation — industry by industry
Industries are o% en thought of in terms of the nations 
that have launched the greatest innovations.  " ere 
is a perception of a U.S. automotive industry pitted 
against a Japanese industry, for example, or the 
U.S. pharmaceutical industry against the European 
industry.  Globalization has, however, rapidly 
changed the underlying nature of these competitive 
relationships.  As in the personal-computer industry, 
where components are designed and developed 
worldwide and manufacturing is largely performed 
in China, most knowledge-intensive industries have 
become modular. 
Basic supply chains and distributor networks are 
today becoming increasingly fragmented.  " ey are 
now characterized by a diversity of business models, 
a multitude of players, and a global footprint.  Like a 
set of building blocks, these business components can 
be reconnected in di# erent and sometimes surprising 
ways.  Mass communication, low-cost computing, 
and global talent have enabled small- and mid-sized 
corporations to act in capacities impossible only a 
decade ago.  Countries like India and China have 
been major bene$ ciaries of this trend.  In certain 
industries, these nations are on the way to becoming 
hubs of research and development for the global 
market.
" e Global Engineering and Entrepreneurship 
project at Duke University has been focused on the 
e# ect of globalization on the engineering profession 
and the sources of U.S. competitiveness.  We have 
researched topics including engineering education in 
India, China, and the U.S.; the reasons engineering 
and technology companies are going o# shore; 
the e# ect of immigrants on the U.S. economy; 
intellectual-property creation and entrepreneurial 
activity in the U.S.  To better understand the 
globalization of innovation, we looked in-depth at 
several knowledge-intensive industries in India and 
China, the major countries undergoing the swi% est 
change.
We have researched the globalization of several 
industries by analyzing the shi%  of intellectual-
property creation through global patent $ lings, 
economic data, global value-chain analysis, and 
extensive $ eld research.  " e analysis of patent 
and economic data provided some useful insights, 
but we believe that our $ eld research was the most 
e# ective method for understanding the globalization 
phenomenon.
We will present our $ eld analysis in the context of 
the industry global value chains we de$ ned.  For this 
research, we made several trips to India and China 
and interviewed the executives of approximately 
115 $ rms in the pharmaceutical, semiconductor, 
automotive, aerospace, cell-phone, and computer-
networking industries.  We toured their research 
labs, met heads of research and development (R&D) 
and local researchers, interviewed customers, 
and reviewed many of the technologies under 
development.  We also interviewed academics at 
several universities and government o!  cials in the 
local regions.
Here we present our analysis of the 
pharmaceutical industry, incorporating a value-chain 
analysis and company summaries of 16 Indian and 
Chinese pharmaceutical $ rms that highlight current 
business trends and transformations.
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Multinational corporations are searching for means 
to broaden their capacity for drug development while 
decreasing costs.  Pharmaceutical $ rms in India and 
China are increasingly forging partnerships with these 
corporations to gain revenue and to develop their 
own expertise.  " ese relationships largely appear to 
be symbiotic.   
As a result of the movement of R&D to their 
countries, Indian and Chinese scientists are rapidly 
developing the ability to innovate and create their 
own intellectual property.  Several $ rms in India 
and China are performing advanced research and 
development and are moving into the highest-value 
segments of the pharmaceutical global value chain. 
What is noteworthy is that most of the advances 
in R&D in India and China happened over the last 
decade with the greatest momentum being built over 
the last $ ve years. 
Global pharmaceutical intellectual-
property creation
In 2006, 5.5 percent of all global pharmaceutical 
patent applications (WIPO PCT applications) 
contained one inventor or more located in India, and 
8.4 percent contained one or more located in China.  
" is increased fourfold from 1995. 
Business relationships
Despite issues with intellectual property, 
multinationals are $ nding greater scope for 
cooperation with several companies in India and 
China. " ey have developed a broad range of 
relationships, which generally seem to have been 
successful and to be expanding in magnitude and 
scope. " ese include:
1. Original proprietary research: Several Indian 
and Chinese $ rms are developing their own 
proprietary drug products targeting global or 
regional markets, but they lack the ability to 
advance a drug through the entire clinical-trial 
process and market them worldwide.  " ese 
companies seek licensing agreements with, 
or make complete drug sales (i.e. inclusive 
of supportive clinical data) to, multinational 
pharmaceutical companies that have the necessary 
resources.
2. Research partnership: In these relationships, a 
multinational corporation supplies a research 
partner with an early- or mid-stage drug 
candidate and contracts the partner to develop it 
further.  " e domestic $ rm gains access to a novel 
compound(s) and potential assistance from its 
multinational partner, which in turn expands its 
own drug-development capabilities.  A number 
of these deals involve cost and risk sharing in 
exchange for joint ownership of the intellectual 
property.
3. Contract research organizations (CROs): " ese 
$ rms are typically contracted to perform speci$ c 
stages of drug discovery, development, or testing, 
and receive a $ xed payment upon reaching a 
predetermined milestone.  Companies using this 
model do not assume any of the risk, positive 
or negative, associated with drug development.  
Several companies in India and China are 
specializing within speci$ c disease types or within 
speci$ c functional areas of the pharmaceutical 
value chain.
4. Generics, APIs, and manufacturing: India (and to 
a lesser extent, China) has a vibrant generics and 
active pharmaceutical ingredient (API) market.  
Companies that focus on this market carefully 
monitor the intellectual-property protection of 
major drug products.  When a product comes o# -
patent, they explore means of mass-producing the 
drug using identical or similar chemical reactions.
Value-chain activity
1. Indian and Chinese companies are making strides 
in the highest-value segments of global value 
chains.  In the lower-value segments, such as 
preclinical testing, animal experimentation, and 
manufacturing, however, Chinese $ rms appear to 
be more prevalent.
Summary of  ndings
3The Globalization of Innovation: Pharmaceuticals
2. India is regarded as a more mature destination 
for chemistry and drug-discovery activities than 
China.
3. Domestic Indian and Chinese $ rms rarely have 
the capital and the regulatory expertise to develop 
a drug beyond phase II clinical trials.  " eir 
commercial development of new intellectual 
property therefore necessitates relationships with 
major multinational corporations.
Examples of Pharmaceutical 
Opportunities in India and China
1. Indian and Chinese $ rms, including Dr. Reddy’s 
Laboratories, Glenmark, WuXi PharmaTech 
(NYSE:WX), and Hutchison MediPharma, are 
developing proprietary drug candidates, with the 
intent of forging marketing partnerships with 
pharmaceutical multinationals.  Glenmark has 
already successfully completed several licensing 
agreements.
2. Dr. Reddy’s Laboratories can conduct preclinical 
trials for 40 to 60 percent less than the cost 
of comparable activities in the U.S.  Similarly, 
Aurigene can conduct chemistry work for a 
quarter of the cost. 
3. A% er Eli Lilly was unable to collect a series of 
speci$ c human tissue samples in the U.S., the $ rm 
contracted ShanghaiBio, which was able to collect 
100 relevant samples in China in the course of 
three weeks.
4. In the U.S., tissue collection can cost as much 
as USD 2000 per sample.  In China, this can be 
accomplished for around USD 300 per sample.
5. Pharmaceutical multinationals have begun 
partnering with Indian $ rms to conduct $ xed-
dose-eruption skin-reaction tests.  Competition 
has now signi$ cantly reduced the cost of this 
work, from USD 80,000 to approximately USD 
30,000.
6. In China, employees holding PhDs from top 
universities can be hired for salaries of around 
USD 15,000 per year. 
7. By developing drugs and selling them in markets 
without product-patent enforcement, Cipla, an 
Indian pharmaceutical $ rm, has been able to 
provide anti-AIDS medication to India and Africa 
for around $300 per patient per year, one-fortieth 
to one-$ % ieth the cost of competing treatments.
Other observations
1. Indian $ rms appear to be able to attract U.S.-
educated and -trained scientists and engineers 
more readily than their Chinese counterparts.
2. In both India and China, a number of 
pharmaceutical $ rms competing for regional 
generics markets aspire to enter new-drug 
development in the next $ ve years
3. Despite a leap in the number of clinical trials 
in India and China, the total numbers remain 
small compared with the U.S. and Europe.  As of 
late May 2008, the National Institutes of Health’s 
clinicaltrials.gov identi$ es more than 56,000 
studies worldwide, including32,410 in the U.S., 
750 in China, and 670 in India.  " ese $ gures 
include current and completed clinical trials.  
When it comes to current clinical trials alone, the 
London-based Business Monitor International 
(BMI) in Asia Paci! c Pharma and Healthcare 
Insight (May 2008) ranks Japan $ rst in the Asia 
region with 406 studies, followed closely by China 
(389) and India (347).  As recently as November 
2007, BMI gave China a slender 274–260 lead over 
India in current clinical trials.
4. India’s Planning Commission is claiming in 2008 
that India is overtaking China in number of recent 
clinical trials, but the jury is still out.
SUMMARY OF FINDINGS
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Rank Company Global sales Global Market-share 
percentage
1 Pfi zer (USA) USD 45.1 bn 6.3%
2 GlaxoSmithKline (UK) USD 39.2 bn 5.5%
3 Sanofi –Aventis 
(France)
USD 37.4 bn 5.3%
4 Novartis (Switzerland) USD 29.5 bn 4.1%
5 AstraZeneca  (UK) USD 25.7 bn 3.6%
6 Johnson & Johnson 
(USA)
USD 23.3 bn 3.3%
7 Merck   (USA) USD 22.6 bn 3.2%
8 Roche (Switzerland) USD 16.9 bn 2.4%
9 Wyeth (USA) USD 15.7 bn 2.2%
10 Eli Lilly (USA) USD 14.8 bn 2.1%
Introduction: The pharmaceutical industry
" e creation of a new drug requires signi$ cant capital 
investment.  Pharmaceutical companies in search 
of novel drugs or means of treating documented 
symptoms must navigate pitfalls in early drug 
discovery and meet regulatory criteria for clinical 
trials.  Food and Drug Administration (FDA) 
regulation of drug development makes the discovery 
cycle one of the longest of any industry: it is not 
unheard of for a decade to pass between an initial 
drug discovery and commercial availability.
To add to the industry’s woes, a number of 
established blockbuster drugs held by major 
pharmaceutical companies will go o# -patent in 
2008 and 2009, leading to a sizable decrease in 
revenues amidst mounting competition from generics 
producers.
In 2005, the largest ten pharmaceutical companies 
by market share controlled more than 42 percent of 
the global pharmaceutical market, as opposed to a 
30 percent share ten years earlier (Bertoncelj).  " is 
can be attributed mainly to consolidation through 
mergers and acquisitions.  In 2007, their market share 
had fallen four points, to 38 percent. Table 1 lists the 
top ten sales leaders in 2007 according to the annual 
survey of Pharmaceutical Executive magazine (May 
2008).
" e contribution of emerging markets to global 
industry sales growth has increased from 13 percent 
in 2001 to 27 percent in 2006.  Particularly strong 
growth occurred in China (by 15.9 percent), India 
(14.0 percent), South Korea (11.9 percent), and Brazil 
(10.9 percent) (Standard & Poor’s, 2007).  " ough 
smaller than established western and European 
markets, emerging markets are becoming increasingly 
important.  With these changing market dynamics, 
pharmaceutical multinationals are updating their 
strategies and business models to pursue new 
relationships with $ rms in emerging markets.  
" is paper will explore the role that India and 
China, the fastest-growing markets, play in the 
pharmaceutical industry.  See Appendix A for 
de$ nitions of some of the technical terms used.
Table 1: Top ten global pharmaceutical fi rms — 2007 global sales
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Global value chains: an introduction
A value chain is the series of related activities that 
contribute to the production and delivery of a speci$ c 
product or service.  " ese activities include design, 
production, marketing, distribution, and support.   
Much of the contemporary value-chain literature 
has focused on mapping out global production and 
sourcing networks that link leading manufacturers, 
retailers,liter and marketers to their suppliers located 
around the world.  However, the newest phase of 
globalization involves setting up and managing 
innovation and design networks across countries 
in di# erent regions of the world. " e value-chain 
framework helps us understand the structure and 
dynamics of these global innovation networks.
As companies’ understandings of industry 
dynamics have matured along with their own 
core competencies, more complicated value-chain 
relationships have emerged.  Today, value chains in 
many industries include various players in diverse 
countries.  " e e# ects of production facilities, design 
centers, and distribution channels on each other are 
tightly controlled and managed internationally.  " e 
rising complexity of these value chains has brought 
signi$ cant new opportunities and vast challenges.  
Global value chains have enabled corporations to take 
advantage of international talent, expand research 
and production capacity, and reduce development 
periods.  But there are risks as well as rewards: 
through global diversi$ cation, control over speci$ c 
tasks is diluted; loss of intellectual property becomes a 
greater concern; stage connectivity is threatened; and 
global trade regulations add new layers of restrictions. 
Relationships of power, control, and interdependence 
illustrated through global value chains are shaping the 
future of domestic and international business.
In recent years, the concepts of value-chain 
modularity and fragmentation have emerged as a way 
to explore the physical separation of interdependent 
value-chain stages.  " ough the uncoupling of value-
chain stages is not a new phenomenon, its growing 
international focus represents a departure from 
previous industry trends (Arndt, 2001).  Recent mass 
“o# shoring” and “outsourcing” of speci$ c functional 
groups within business units e# ectively demonstrate 
both value-chain modularity and international 
value-chain governance.  In the global economy, 
this disintegration of production has led toward an 
integration of trade (Feenstra, 1998).  Multinationals 
today employ modular value chains in an e# ort to 
take advantage of emerging markets, international 
talent pools, and global trade.
Research in the last decade has suggested that 
the geographic dispersion of multinational activities 
has acted as a source of knowledge creation.  " e 
decentralization of R&D and innovation activities is 
commonplace among large businesses today.  " ough 
a signi$ cant portion of innovation work remains 
tied to a corporate headquarters, the draw of human 
capital, and to a lesser extent market and technology 
access, are major drivers toward international 
fragmentation.
" e internationalization of R&D and innovation 
activities requires a substantial commitment of 
resources.  " ough commonly used to eliminate 
or reduce the need for product localization, R&D 
internationalization has also increased the spillover 
of valuable technology competencies to local 
competitors.  A critical factor in the success of a 
fragmented R&D network has been the e!  ciency of 
endogenous technology transfers between distant 
branches (Sanna–Radaccio and Veugelers, 2007).
" ough value chains and supply networks are 
o% en represented as orderly progressions between 
distinct tasks or functions, these relationships 
are rarely one-dimensional.  Vertical movement 
in traditional value chains is the progression of a 
product through its sequential development and 
production cycle.  In contrast, through horizontal 
movement, companies explore opportunities to 
pursue relationships with outside $ rms in similar 
stages of the value chain.  Horizontal movement could 
lead to new markets, cost-saving partnerships, or 
innovation opportunities.  Finally, diagonal movement 
seizes integrative opportunities in other value chains 
and even in di# erent segments.  Diagonal connections 
may be used to mitigate risks or identify new 
applications (Pil and Holweg, 2006).
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The pharmaceutical global value chain
A global value chain is the series of related 
activities carried out between and within $ rms that 
contribute to the production and delivery of a given 
product or service across national boundaries.  " e 
pharmaceutical value chain is characterized by drug-
discovery and drug-development activity, to identify 
promising pharmacological candidates; clinical trials, 
to demonstrate the safety and functionality of these 
drugs in human subjects; and manufacturing, to mass-
produce approved drugs through scalable high-yield 
chemical reactions.  " e sequences of these stages can 
be found in Figure 1.
Drug discovery and development
New pharmaceutical drugs largely fall into one 
of three distinct categories: new-concept drugs, 
precedented drugs, and generics.  A new-concept drug 
is the ! rst molecule designed to address a particular 
drug target.  Drug targets are typically de$ ned by a 
series of reactions leading to a disease or condition 
that can be a# ected through treatment.  New-
concept drugs are the most expensive to develop; in 
many cases, they depend on new research lines or 
biological-pathway models.
" e majority of drugs actively in development can 
be classi$ ed as precedented drugs.  " ese drugs rely on 
scientists’ understanding of a documented drug target 
and the related functionality of existing drugs.
Finally, the manufacture of generic drugs uses the 
publicly available intellectual property documenting 
existing compounds that no longer qualify for patent 
protection.  Generics markets vary signi$ cantly 
internationally, necessitating special e# orts to abide 
by national laws that govern their distribution and 
sale.
Drug discovery and development for new-
concept and precedented drugs is a complicated and 
iterative process.  " e $ rst step is the identi$ cation 
of a drug target.  " is usually involves locating a 
speci$ c series of biological events related to a disease 
Figure 1: The global pharmaceutical or 
pharmaceutical global value chain
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process.  Identifying this series allows researchers 
to predict means of emulating, disrupting, limiting, 
or otherwise a# ecting that particular pathway.  
Researchers then engage in compound generation 
and screening, a process in which many biological 
compounds are collected and tested for any e# ect 
on the drug target.  " e compounds with the largest 
potential e# ects undergo lead optimization and 
development, a complicated non-linear cycle of 
chemical enhancement.  Ultimately a drug candidate 
is produced.
Clinical trials
" e FDA requires that a series of demanding clinical 
trials demonstrate a drug candidate’s toxicology, 
e!  cacy, and speci$ city.
Preclinical testing monitors the e# ects of the drug 
when it is assimilated into a biological system, and is 
performed on animals and through laboratory tests.
Phase 0 clinical trials (not shown in Figure 1) are 
an optional $ rst round of tests on human subjects 
and involve the delivery of very small drug quantities, 
called microdoses.  " ese tests are designed to 
eliminate poorly performing drugs early and may 
obviate phase I.
Phase I clinical trials are generally conducted 
on a small body of healthy volunteers to test a drug 
candidate’s safety and biological e# ects on humans.
" ese are followed by phase II clinical trials, 
designed to assess drug functionality and build upon 
safety $ ndings obtained from phase I trials.  Phase 
II trials are conducted on larger patient groups and 
gather information on the e!  cacy and safety of 
various dosages.
Phase III trials o% en represent a bottleneck in 
clinical trial development, as these are the most 
costly, time-intensive, and complex to run.  " ey 
involve patient groups of hundreds or thousands of 
volunteers, depending on the target condition.
Phase IV clinical trials track a drug candidate 
for long-term safety e# ects a% er a drug has been 
approved for commercial sale.
Manufacturing
To deliver a potential drug from a laboratory or small-
scale testing environment to national or international 
patient populations requires reliable control of 
chemical reactions and manufacturing dynamics.  
In mass production, raw materials are combined in 
high-yield chemistry.  Identifying scalable, simple, 
cost-e# ective chemical reactions by which to produce 
large quantities of a target drug is essential.  " ese 
reactions produce drug intermediates and active 
pharmaceutical ingredients that are the building 
blocks of $ nalized drugs.  Some pharmaceutical 
manufacturing companies mass-produce these 
intermediate components for consumption by other 
pharmaceutical entities.  " rough further processing 
and additional chemical reactions, a $ nal drug 
product emerges for distribution.
8The Globalization of Innovation: Pharmaceuticals
In the previous section, we outlined the stages 
involved in the pharmaceutical value chain, covering 
progression through drug discovery and development, 
clinical trials, and manufacturing.  A drug 
candidate’s development o% en proceeds linearly, but 
pharmaceutical corporations can extract maximum 
value from this chain by searching for vertical 
opportunities present in competing or partnering 
$ rms.  " ese possibilities appear in Figure 2.
Vertical opportunities in the pharmaceutical value chain
Within drug discovery and development, a number 
of internal and external opportunities exist for 
companies to enlarge their populations of candidate 
drugs.  Internally, new-concept drugs or precedented 
drugs can be identi$ ed through novel and existing 
analytical and screening tools.  Similarly, product 
extensions or variants can be created based on 
existing drug families with aging intellectual-property 
protection (patent evergreening).  Drug candidates 
can also be acquired externally through corporate 
acquisitions; the purchase of promising intellectual 
property; or research programs with universities.  
Many large and multinational corporations have 
also begun engaging contract research organizations 
(CROs) to develop low- and mid-priority drug 
candidates.  Finally, in an e# ort to minimize the 
increasing costs of discovery and development, 
large pharmaceutical companies are turning to 
value-sharing and milestone-based partnerships 
with trusted small- and mid-sized pharmaceutical 
companies in developing countries.
Internal and external opportunities also 
exist in time- and cost-intensive clinical trials.  
Pharmaceutical companies with prior experience 
in navigating FDA clinical trials and international 
regulatory agencies routinely use their sta# ’s 
knowledge and expertise in clinical-trial standards 
to maximize e!  ciency in order to expedite drug 
Figure 2: Vertical pharmaceutical opportunities
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VERTICAL OPPORTUNITIES
approval.  " e trials’ high costs have encouraged 
the formation of new business relationships and 
external services designed to mitigate them.  A 
business approach popular with small- and mid-
sized pharmaceutical companies is to develop drug 
candidates through proof of concept, in an e# ort 
to maximize the candidate’s value before selling its 
intellectual property to a larger corporation with the 
$ nancial resources to navigate phase III clinical trials.  
CROs and need-based international clinical trials 
are also emerging as means to reduce the cost of the 
clinical-trial process.
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Big Pharma has harbored a special fear of 
the intellectual-property practices of India’s 
pharmaceutical industry, which long exhibited a 
mastery of the market for low-cost generics in the 
developing world.  Deutsche Bank’s senior pharma 
analyst, Barbara Ryan, refers to the “cannibalistic 
e# ect of generic substitution.”  Indian generics 
manufacturing hardly stands alone in facing such 
indictments.  Highlighting the expiration in 2001 of 
Eli Lilly’s patent of Prozac, she notes that the drug 
“lost 90 percent of its value in several weeks when 
generic & uoxetine was introduced” (Gray, 2006).
On the front lines of controversy is Yusuf 
Hamied, of the Indian $ rm Cipla, the world’s largest 
manufacturer of retrovirals.  Former Glaxo CEO and 
Chairman Richard Sykes labels him a “pirate.”  Hailed 
as a hero in the developing world for bringing an 
array of cheap generics to the poor and desperately 
ill, Hamied, a chemist, counter-attacks that Glaxo 
should have been regarded as “a global serial killer” 
for prices more than 30 times higher than Cipla’s 
HIV medicines.  Glaxo was hardly alone in his 
indictment.  Hamied accuses many other global 
$ rms of charging 40 to 50 times more than Cipla’s 
line of retrovirals.  With a family heritage close to 
the Indian independence movement and Gandhi 
himself, Hamied rails against a restrictive British 
patent law of 1911 that le%  a legacy of expensive 
imported drugs lasting into the early postcolonial 
decades, with prices in India exceeding those found in 
pharmacies across Europe.  He fought back and says 
he is proud of Cipla’s scope: “We have more products 
than any [drug] company in the world.  More than 
1000 for humans, and 100 for animals.”  A founder 
of the Indian Drug Manufacturers’ Association, he 
successfully lobbied for the passage of the patent law 
of 1972 that ushered in what the Financial Times calls 
“a golden era for the country’s generic companies” 
(Jack, 2008).
Hamied stresses that he is not an opponent of 
patents, but rather $ ghts monopoly.  Indeed in an 
e-mail he recommends “a system similar to the 
Canadian Bill S-91 of 1969”, which grants a “payment 
of four percent royalty to the originator”.  Under 
pressure to conform to the norms of the Washington 
Consensus and the World Trade Organization, the 
Indian Government has thus far spurned his counsel.
Signi$ cant change is under way, as India adopted a 
stricter regime of patent protection in 2005.  " e law 
did not allow for a transition period and peculiarly 
is backdated to 1995, which Hamied regards as a 
grave injustice.  Within the pharmaceutical industry, 
India previously gave protection to patents on the 
manufacturing process only; now the nation extends 
this to the patenting of drug substances.  Still Indian 
courts reject patent protection on mere “incremental 
innovation”, the process by which a patent is 
“evergreened” well beyond its 16-year allotted span.  
Angry that Indian authorities and courts refused 
patent protection for the leukemia drug Gleevec, 
Novartis has suggested that it will shi%  much of its 
investment from India to China. (Houlton, 2007)  
" is may seem ironic, as many corporate leaders, at 
least in non-pharma industries, regard India as a safer 
haven for intellectual property than China.  Ranjit 
Shahani, president of the Novartis Group in India, 
implores the Indian government to $ nd alternatives to 
lax intellectual-property regimes:
Tiered pricing, donation programs, public–private 
partnerships, and differential pricing are amongst 
the ways to meet the access challenge that are more 
innovative than diluting patents.  Such programs 
can work, provided the government ensures that 
discounted drugs are not re-exported to countries 
that can afford to pay.  (“Novartis’s Ranjit Shahani…”, 
2008)
Defenders of Indian cooperation with stricter 
patent regimes argue that enforcement should 
generate the long-term investment in R&D that will 
yield blockbuster drugs and future cures.  " ey fear 
that devotion to generics is a short-term solution that 
will keep India starved of R&D investments, which 
remain below one percent of GDP for all industries.  
China invested 1.34 percent of GDP in R&D in 2005, 
but the government seeks to nearly double that by 
the year 2020.  If R&D growth can be sustained, 
technocrats in India and China will look for many 
more enterprises to advance on the global value chain.
Storm over intellectual property
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A series of 16 company summaries immediately 
following this paper’s conclusion details the roles 
which a sample of companies in India and China are 
playing in the global pharmaceutical value chain.  
" ey also highlight the strategies and markets these 
$ rms are pursuing.
Our general observations are that multinational 
pharmaceutical companies, acting to broaden R&D 
activities without raising costs, are increasingly 
forging partnerships and research collaborations with 
companies in India and China.  Business relationships 
vary signi$ cantly and include captives, partnerships, 
milestone systems, value-sharing, and direct 
buyouts.  Some of these partnerships entail joint drug 
ownership and/or split-revenue arrangements rather 
than $ xed milestone payments. " e type of work 
assigned includes drug discovery, manufacturing, 
clinical trials, and generics production.
As a result of the movement of R&D to their 
countries, Indian and Chinese scientists are rapidly 
developing the ability to innovate and create their 
own intellectual property.  " is shi%  is evident in the 
increasing prevalence of Chinese and Indian inventors 
on global pharmaceutical patent applications.  " eir 
contributions increased fourfold from 1995 to 2006.
Figure 3 presents a time-dependent analysis of 
global patent applications $ led through the World 
Intellectual Property Organization (WIPO PCT 
applications).
Our  ndings
























Percentage of Pharmaceutical PCT Applications with One or More 
US, Chinese or Indian Inventor, Respectively
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India and China in the global value chain
Indian and Chinese $ rms are increasingly occupying 
higher-value segments of the pharmaceutical value 
chain.  Relatively few $ rms are engaged in the 
discovery and development of new-concept drugs, 
due both to the high initial capital investment such 
drugs require and to their high failure rate.  Instead, 
many corporations are involved in the development 
of precedented drugs and generics. " e large 
populations of India and China make both countries 
exceptional markets for low-cost generic drugs, 
and domestic companies that have succeeded in 
marketing them in volume are using the proceeds 
to fund drug research and development.  " ese 
activities most o% en take the form of either internal 
development of precedented drugs or development of 
the drugs’ intellectual property through partnership 
with a multinational.
Excluding multinational corporations’ research 
divisions, we observed very few $ rms located in India 
and China with the personnel, capital, and expertise 
to successfully push a drug candidate through the 
entire clinical-trials segment of the pharmaceutical 
value chain.  In virtually all cases, local $ rms required 
outside assistance to continue trials through phase 
III, which requires the largest patient pools, research 
periods, and capital investments.
Figure 4 indicates, using bold outlines, the stages 
of the pharmaceutical value chain in which domestic 
Indian and Chinese $ rms are most active.  Value-
chain boxes without bold outlines indicate no or little 
activity at this stage.
Business models and work complexity
" e needs of multinational and emerging 
pharmaceutical businesses have created a symbiotic 
relationship in India and China.  Multinational 
corporations are searching for means to broaden 
their capacity for drug-candidate development and 
decrease costs.  Pharmaceutical $ rms in emerging 
countries realize that developing their own drugs or 
Figure 4: Pharmaceutical value-chain activity of 
Indian and Chinese fi rms
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partnering with multinational corporations will be 
their only means to gain access to the highest-value 
markets and technological expertise.  " is has led to a 
variety of novel pharmaceutical business models.
Original proprietary research:  A number of 
Indian and Chinese $ rms are developing their own 
proprietary drug products for regional and global 
markets.  " ese proprietary e# orts are impressive 
for the range of capabilities and expertise they 
require throughout the pharmaceutical value 
chain.  Drug target selection is based typically on a 
market or humanitarian need.  " ey then navigate 
the complicated process of drug discovery and 
development, involving an array of chemistry, biology, 
and analytical skills.  O% en they advance a proprietary 
drug to proof-of-concept validation, which typically 
occurs at the end of phase II clinical trials.  So 
validated, the candidate drug is more valuable, and 
o% en its owner seeks a licensing agreement with, or a 
complete drug sale (i.e. inclusive of supportive clinical 
data) to, a multinational pharmaceutical company 
with the resources necessary for completing its 
development and global marketing.  Few companies 
in India or China have the $ nancial capability or 
marketing skills to do this on their own. 
In India, Dr. Reddy’s Laboratories employed this 
strategy to internally develop a diabetes-inhibitor 
through phase II clinical trials.  Similarly, the Chinese 
$ rm Hutchison MediPharma has developed a herbal-
medicine extract to treat in& ammatory bowel disease 
and a drug designed to be used in conjunction with 
radiation treatments for advanced head and neck 
cancer; both drugs are currently undergoing clinical 
trials.  Ranbaxy is developing an anti-malaria drug, 
Arterolane (RBx 11160), which is undergoing phase 
IIB clinical trials.
Developing internal proprietary drug candidates 
is a costly, risk-prone venture.  Many $ rms support 
this research by o# ering custom pharmaceutical 
services to outside companies or participating in the 
production of generics and APIs.
Research partners:  A number of domestic Indian 
and Chinese pharmaceutical $ rms have emerged as 
research partners for multinational corporations.  
" e most innovative of these relationships are based 
on value-sharing.  Several $ rms have structured 
deals in which they receive royalty payments or 
partial ownership if a candidate drug reaches the 
marketplace.  In these relationships, a multinational 
supplies a research partner with an early- or mid-
stage drug candidate to develop further.  " e 
domestic Chinese or Indian $ rm gains access to a 
novel compound(s) and potential assistance from 
its multinational partner, which in turn expands its 
drug-development capabilities.
Examples of these value-sharing partnerships 
include collaborations between Ranbaxy and 
GlaxoSmithKline to develop a respiratory 
in& ammation target, and between Advinus and Merck 
to develop a metabolic disease treatment.
Contract research organizations (CROs): CROs 
generally have a range of drug-discovery, drug-
development, and clinical-trial capabilities and cater 
directly to the needs of their customers.  Unlike a 
company developing an internal drug candidate or 
partnering with an outside $ rm, CROs have no vested 
interest in the research lines they are developing.  
A CRO is contracted to perform speci$ c stages of 
drug discovery, development, or testing, and paid 
a $ xed amount when a predetermined milestone 
is reached.  It assumes none of the risk, positive or 
negative, associated with drug development.  CROs 
typically become well-known for specializing within 
disease types or for their practical expertise in speci$ c 
functional areas of the pharmaceutical value chain.
Generics, APIs, and manufacturing:  India and, 
to a lesser extent, China have a vibrant market for 
generics and active pharmaceutical ingredients 
(APIs).  Companies that focus on this market monitor 
the intellectual-property protection of major drug 
products.  When a product moves o# -patent, they 
explore means of mass-producing the drug using 
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Table 2: Business models of interviewed fi rms
chemical reactions identical or similar to those that 
produced the original.  Bioequivalence testing is 
required in order to show the FDA that the generic 
form of the drug is functionally similar to the 
original.
" ese $ rms have a strong understanding of 
e!  cient, high-yield chemical reactions, as well 
as the ability to obtain necessary raw materials 
or to purchase outside active ingredients, drug 
intermediaries, or pharmaceutical products. " eir 
manufacturing capabilities allow them to make 
high-volume sales to regulated and/or unregulated 
markets.  Many pharmaceutical $ rms in emerging 
markets have generics businesses because of the 
relatively low barriers of entry associated with this 
work.  Some have acquired the experience and 
expertise in generics chemistry and manufacturing to 
begin positioning themselves for drug discovery and 
development.
Depending on its size and complexity, a $ rm 
may leverage several of the above models.  Table 2 
below depicts the business models followed by the 
16 pharmaceutical companies our research team 
interviewed for this study.









Generics,    
APIs, and 
Manufacturing
Advinus X X X
AstraZenca China X X
Aurigene X X
Aurobindo X
Biocon X X X
Cipla X
Dabur Pharma X X
Dr. Reddy's Laboratories X X X
Hutchinson Medipharma X X
Novartis China X X X
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" ough a number of domestic Indian and Chinese 
$ rms have emerged as partners in early and mid-
term drug discovery and development, relatively 
few have the resources to develop their own drug 
candidates.  Most $ rms specializing in drug discovery 
and development have expertise in advancing 
candidate drugs through phase II of clinical trials, 
a% er which a drug’s proof of concept can be validated.  
Domestic Indian and Chinese pharmaceutical 
companies, largely lacking the $ nancial capacity 
to advance a drug candidate through phase III 
clinical trials, o% en operate under a business model 
of original proprietary research, research partner, 
or contract research organization (CRO) (listed 
in Figure 4).  A CRO that successfully advances 
a drug candidate to this level of development 
o% en receives a $ xed milestone payment and then 
moves on to a new target.  A research partner may 
receive royalty payments if the drug is successfully 
commercialized a% er clinical trials.  Finally, a Chinese 
or Indian pharmaceutical $ rm engaged in original 
proprietary research would likely seek licensing 
agreements with or make complete drug sales (i.e. 
inclusive of supportive clinical data) to multinational 
pharmaceutical companies that have the resources 
necessary for completing development.
Glenmark, India, has completed several licensing 
agreements with Big Pharma.  In 2006, it licensed 
GRC 8200, an experimental diabetes drug in phase 
II clinical trials, to Merck.  Glenmark was paid USD 
39 million up front, with a potential total payment of 
USD 296 million.  " e collaboration was abandoned 
when Merck elected to pursue treatments for diseases 
other than diabetes.  In 2007, Glenmark completed 
a licensing agreement with Eli Lilly, involving 
a portfolio of TRPV1 receptors and a clinical 
compound named GRC 6211, undergoing phase II 
clinical trials.  It was paid USD 45 million, with the 
potential to earn an additional USD 215 million based 
on milestone performance.  Under the terms of the 
agreement, Glenmark will receive royalty payments 
if GRC 6211 is commercialized.  In April 2008, the 
company received FDA approval to begin phase I 
testing of GBR 500, a monoclonal antibody under 
development for potential treatment of multiple 
sclerosis, chronic obstructive pulmonary disease, and 
in& ammatory bowel disease.
Dr. Reddy’s Laboratories is an example of an 
Indian $ rm that is pursuing parallel approaches 
to obtaining revenue at di# erent stages in the 
pharmaceutical value chain.  Dr. Reddy’s has a strong 
generics- and bulk-manufacturing business that it 
uses to fund its own discovery and development of 
novel drugs.  Four-$ % hs of Dr. Reddy’s discovery 
work is on precedented drugs; about a $ % h of its 
research e# ort focuses on unprecedented therapeutic 
areas (i.e. new-concept drugs).  With a global sta#  
of more than 9000 employees, Dr. Reddy’s seeks to 
advance drug candidates through early phase II trials 
and then license or sell their intellectual property 
to major pharmaceutical players.  Dr. Reddy’s has 
already had some initial success using this strategy 
for a best-in-class diabetes-inhibitor molecule, 
which it licensed to a major diabetes company for an 
advance payment of approximately USD 3 million.  
In 1997, Dr. Reddy’s licensed a drug candidate 
named Ragaglitazar, with the potential to moderate 
diabetic dyslipidaemia and blood-glucose levels, to 
Novo Nordisk.  Although this drug candidate was 
very promising in phase I and II trials, in phase III 
it was identi$ ed as a carcinogen.  " e drug and its 
development had to be abandoned, but the drug’s 
commercial potential had been signi$ cant: 1 mg was 
more than 40 times as powerful as the comparable 
USD 3 billion diabetes drug on the market.  Dr. 
Reddy’s continues to grow its drug-development 
capacity and to pursue novel research candidates.
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Many $ rms are moving to value-sharing relationships. 
Examples are:
Aurigene — Forest; Novo Nordisk; Johnson & 
Johnson; MerckSerono
Hutchison MediPharma —  Eli Lilly and Company; 
Merck; Procter & Gamble
Ranbaxy — GlaxoSmithKline, Merck; PPD
Advinus " erapeutics — Merck
Suven Life Sciences — Eli Lilly
Syngene — Bristol–Myers Squibb 
Chembioteck — Forest
Jubilant Organosys —  Eli Lilly and Company
GVK Biosciences — Wyeth
Nicholas Piramal — Eli Lilly and Company; Merck.
Aurigene, India, provides risk-sharing, milestone-
based drug-discovery services to large pharmaceutical 
$ rms.  " ough a small player, employing just over 
220 scientists, the company is engaged in more than 
ten running discovery programs.  Its clients include 
Forest Labs, Johnson & Johnson, Orion, Novo 
Nordisk, MerckSerono, Debio, Elan Pharma, and 
RheoScience.  
Hutchison MediPharma, China, is developing 
treatments for cancer and auto-immune diseases.  
It follows risk- and reward-sharing models to 
generate revenue by forming research partnerships 
and licensing its drug products that have reached 
the advanced stages of development (prior to phase 
III clinical trials).  " ese revenues come primarily 
through milestone payments and drug-sale royalties.  
" e company has partnerships with Eli Lilly, Merck 
KGaA (Germany), and Procter & Gamble.
Ranbaxy, India, prides itself on its drug-discovery 
and -development capabilities.  Its 1400 scientists 
research new drug-discovery and drug-delivery 
systems.  " e company is collaborating with 
GlaxoSmithKline (GSK) and Merck on preclinical 
testing.  Its partnership with GSK is risk/reward- and 
milestone-based, for pharmacokinetic, toxicity, and 
selectivity analysis on a GSK drug candidate.
Advinus " erapeutics, India, is developing drugs 
for in& ammatory, metabolic, and neglected diseases 
through partnerships with Merck and the Drugs for 
Neglected Diseases Institute.  " e company receives 
milestone-based payments for developing drug 
candidates to proof of concept in phase II clinical 
trials.
Contract Research Organizations (CROs) provide 
research in drug discovery and development, pre-
clinical testing, and early clinical trials.  Firms 
such as ShanghaiBio and Wuxi PharmaTech follow 
this model.  CROs rarely employ value-sharing 
relationships, instead relying on $ xed-payment 
systems.
Many pharmaceutical $ rms in India and China 
have a strong understanding of e!  cient, high-yield 
chemical reactions, as well as the ability to obtain 
necessary raw materials or to purchase outside active 
ingredients, drug intermediates, or pharmaceutical 
products.  " eir generics businesses occupy only the 
shortened generics blocks of the drug-discovery and 
-development and clinical-trials value chains, which 
entail patent-monitoring and bioequivalence-testing.  
" eir manufacturing capabilities allow them to pro$ t 
from high-volume sales.
Local advantages
Most Indian and Chinese pharmaceutical $ rms 
are quick to extol the bene$ ts of locating speci$ c 
drug-development activities within their respective 
countries.  " ey claim a cost advantage in terms of 
personnel costs, facilities, and land.  Government tax 
incentives and development options are also available; 
nevertheless, some executives argue that additional 
programs are needed in order to properly promote 
the pharmaceutical industry.
Development of human capital and an increase 
in Indian and Chinese returnees with U.S. education 
and/or business experience have also contributed to 
the rapid growth of these industries.
Cost savings
Cost arbitrage has been an enticement for 
multinational pharmaceutical $ rms to seek 
partnerships or contracted service relationships with 
Chinese and Indian $ rms.  Figure 5 portrays the 
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1. Estimates provided by Dr. Jason Jin, President and CEO 
of ShanghaiBio Corporation
2. Estimates provided by Mr. C.S.N. Murthy, CEO of 
Aurigene Discovery Technologies Ltd.
Figure 5: Sample pharmaceutical cost savings 
through partnerships with ShanghaiBio 
Corporation (China) and Aurigene (India) relative 
to U.S. pricing
magnitudes of cost savings that ShanghaiBio in China 
and Aurigene in India say that they can provide for 
their customers in the segments of the pharmaceutical 
value chain concerned with drug discovery and 
development and preclinical trials.  " ese potential 
savings are relative to U.S. pricing and vary according 
to the type and complexity of the biological, chemical, 
or analytical work and quantity of biological samples 
required.
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Ethical issues and constraints on future growth
welfare law in 2004 encountered bitter public hostility 
when some opponents contrasted the acute poverty of 
the poorest 135 million Chinese, who subsist on less 
than one dollar per day, with the supply to monkeys 
of music, toys, and puri$ ed water.  " e purchase price 
for monkeys in China is estimated at one tenth that 
in the U.S., but scientists at the Kunming Primate 
Research Center (KPRC) and Beijing University’s 
Institute of Molecular Medicine (Beida-IMM) admit 
that e# orts to attain from the AAALAC (Association 
for Assessment and Accreditation of Laboratory 
Animal Care) accreditation for humane treatment 
have sent maintenance costs spiraling.  Estimating 
the annual cost of maintaining monkeys at 25,000 
Yuan per year (USD 3,500), biophysicist Zhou 
Zhuan, of Beida-IMM, exclaims that when meeting 
international standards, “Chinese monkeys are far 
more expensive than we ever imagined”, ending up 
negating a substantial portion of the price di# erential 
between non-human primates held in China and 
those held in the U.S. (Hao, 2007; Mandavilli, 2006).
When it comes to medical experimentation on 
humans, China faced a human rights uproar when 
Deputy Health Minister Huang Jiefu conceded in 
2005 that organs are taken from executed prisoners 
in order to carry out transplant surgeries.  Amnesty 
International claims that China executes more 
prisoners than the rest of the world combined 
(Macartney, 2008).  Both India and China remain 
vulnerable to accusations of abuses in testing 
protocols, especially because these nations are 
experiencing escalating shortages of trained 
inspection personnel.  According to a report of India’s 
Planning Commission, “" ere is a lack of world-class 
testing laboratory [sic] for validation of tests.  Most 
importantly, there is a looming shortage of clinical-
research personnel estimated at 30,000 to 50,000” 
(“No world-class lab…,” 2008).  Speci$ cally, India 
needs trial investigators, auditors, and o!  cials capable 
of serving on ethics and data-safety–management 
boards.  " e O!  ce of the Drugs Controller in 
particular su# ers from understa!  ng (Sinha, 2008).  
Although Indian and Chinese pharmaceutical 
companies have made substantial progress, there 
are signi$ cant constraints on future growth.  Several 
domestic Indian companies were able to achieve 
early growth by relying on national patent laws that 
only recognized process patents.  " ese companies 
were able to capitalize on internationally disclosed 
intellectual property and to fashion generic drugs 
based on the compounds described, for sale in 
markets unrestricted by product patents.  " e success 
of this strategy is subject, however, to national 
intellectual-property laws, which in some cases are 
being replaced by new regulations covering product 
patents.
International outsourcing can lead to backlashes 
and unforeseen risks.  Illinois-based Baxter 
International came under a glaring spotlight for 
its blood thinner heparin, evidently contaminated 
through an active pharmaceutical ingredient 
manufactured by Changzhou SPL, located near 
Shanghai.  Neither the FDA nor the Chinese 
regulators had previously inspected this plant, but 
reports of 20 deaths led to the descent of an FDA and 
media throng on the factory.  Partisans of the FDA 
are demanding the hiring of more inspectors for this 
global work as well as a state-of-the-art data system 
to monitor drug imports.  Democrat Bart Stupak, the 
chair of the U.S. House Subcommittee on Oversight 
and Investigations, is pondering legislation that could 
“prohibit the marketing of any drug from a plant that 
has not been properly inspected” (Wechsler, 2008).
" ere are other potential & are-ups of unrest.  
China is second in the world in experimentation 
on non-human primates.  " ough still well behind 
the U.S., which used 54,998 monkeys for research 
in 2004, “China is preparing to become the world’s 
supplier of research primates”, according to Nature 
Medicine (March 2006).  Ambitious talk abounds of 
expanding primate colonies and research facilities, the 
sort of colossal testing regimes that could antagonize 
animal-rights activists worldwide.  E# orts by the 
Beijing municipal government to initiate an animal-
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ETHICAL CONSTRAINTS
Having executed the head of the State Food and Drug 
Administration (SFDA), Zheng Xiaoyu, in July 2007 
on charges of corruption, China’s government also 
confronts anxieties about severe long-term shortages 
of regulatory personnel for the torrid growth sector of 
clinical trials.
Partly due to its evaluation of regulatory 
conditions, A.T. Kearney’s “Country Attractiveness 
Index for Clinical Trials” (Pharmaceutical Executive, 
May 2007) still rates the U.S. (at 6.68) signi$ cantly 
ahead of China (6.10) and India (5.58), though the 
latter two nations have big advantages in terms of (1) 
cost e!  ciencies and (2) enormous drug-naïve patient 
pools.  Business Insights, a U.K. $ rm specializing 
in strategic market analysis, has forecast a tenfold 
leap in clinical trials in India from 2006 to 2011 
(Mirasol, 2007).  " e total global market in clinical 
trials will reach USD 30 billion in 2008.  " e Planning 
Commission of India in April 2008 cites estimates 
that the value of the Indian clinical trials sector stands 
at USD 300 million, with projections of USD 1.5 
to 2.0 billion by 2010.  Elsewhere, there have been 
similarly ambitious predictions for growth in China.  
" ough growth rates have been less spectacular so 
far in India and China, both nations are experiencing 
a signi$ cant surge in experimentation and clinical 
trials.  In 2006 alone, India posted 65 percent 
growth in clinical trials, and in early 2008 the India 
Pharmaceutical Alliance reports that ten out of 
eleven of the world’s largest global pharmaceutical 
$ rms have several clinical trials underway in India: 
GlaxoSmithKline (22 clinical trials), Johnson & 
Johnson (22), Eli Lilly (17), Bristol-Myers Squibb 
(17), P$ zer (16), Sano$ -Aventis (15), AstraZeneca 
(10), Novartis (9), Merck (8), and Roche (5) (Sinha, 
2008).  " ough many analysts regard the growth of 
India and China in clinical trials as a juggernaut, a 
regulatory breakdown similar to the heparin scandal 
could mobilize key members of the U.S. Congress and 
turn public opinion against further o# shoring of drug 
testing.
" ough multinational companies are increasing 
the number and complexity of business relationships 
with external partners, they guard against accidental 
disclosure or loss of intellectual property by not 
actively assigning their most lucrative projects to 
them.  " is prevents Indian and Chinese partners 
from working on some of the most innovative 
and cutting-edge projects.  " e multinational $ rm 
P$ zer has not yet established any risk-sharing R&D 
partnerships with Asian companies, instead building 
a network of CRO partners to support its research 
projects.
Availability of talent and human capital continues 
to be a signi$ cant concern in both countries.  " ough 
Indian returnees, and to a lesser extent Chinese 
returnees, are available today in greater numbers than 
in years past, many pharmaceutical employees have 
limited experience with drug-discovery culture and 
the iterative, non-linear nature of important lead-
optimization activities.
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Cost pressures, the need to tap global talent, and 
growth opportunities in emerging markets have 
prompted western pharmaceutical companies to shi%  
substantial manufacturing and clinical-trial work 
to India and China.  Big pharmaceutical companies 
such as Merck, Eli Lilly, and Johnson & Johnson are 
now counting on these countries for research and 
development as well.  Both nations have become 
major partners in preclinical and clinical testing.  
China, for example, has a very wide network of 
hospitals from which to draw human tissue samples 
and live patients. China is also a major supplier of 
non-human primates for testing.
At $ rst, the aim of Big Pharma was to bene$ t 
from the lower labor and overhead costs of India and 
China.  Increasingly these companies are turning to 
Asia to broaden the range of new drug candidates.  
Because Indian drug companies are those with the 
most experience in selling generic drugs in the U.S. 
that meet FDA standards, India is playing a more 
strategic role in early discovery.  Companies such 
as Ranbaxy, Aurigene, Advinus, Nicholas Piramal, 
and Jubilant have negotiated long-term deals with 
western pharmaceutical companies to discover and 
develop new chemical entities.  In a growing number 
of cases, the Indian companies share the $ nancial risk 
in discovery as well as the potential $ nancial rewards.  
One Chinese company, Hutchison MediPharma, has 
formed a similar partnership with Eli Lilly.  Others 
are likely to follow suit as Chinese contract research 
organizations gain experience and western companies 
come to trust in China’s ability to protect intellectual 
property.
It is too early to tell whether China and India will 
become important sources of new drugs.  In contrast 
to industries such as so% ware and electronics, in 
which there has been substantial growth in o# shore 
R&D, the pharmaceutical industry takes many years 
for a new product to survive the process of clinical 
testing and regulatory approval.  Most of the new 
risk-sharing arrangements date from 2005, so it could 
be another decade before there are concrete results.
" e early progress, however, is promising.  Several 
companies, such as Ranbaxy, Advinus, Nicholas 
Piramal, and Aurigene, have achieved signi$ cant 
development milestones with new chemical entities.  
Several drugs from these partnerships are going into 
clinical testing.  As a result, more work is likely to be 
outsourced, and the trend of R&D moving to these 
countries is likely to increase.
Conclusions
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Here we present speci$ c discussions of the types 
of pharmaceutical activities that various regional 
and international pharmaceutical corporations are 
engaged in.  We conducted detailed interviews with 
16 pharmaceutical $ rms in China and India to obtain 
information on their business models, value-chain 
activities, partnerships, and technology capabilities.  
Data presented in these summaries were obtained 
through a mix of interviews with company executives, 
company press releases, and site visits.
Company summaries
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Business model: contract research organization; drug-
discovery collaborations; original discovery research
Active value-chain segments (highlighted in blue):
Advinus Therapeutics
Company history
Advinus " erapeutics (Advinus) was founded in 
2005 by the company’s CEO, Dr. Rashmi Barbhaiya, 
who brought  21 years of experience at Bristol–Myers 
Squibb.  Dr. Barbhaiya aimed to take advantage of 
the talent and resources available in India to cater to 
the growing demand for discovery and development 
of new drugs.  He had worked with several of India’s 
largest pharmaceutical companies and fostered 
several alliances between Ranbaxy and international 
companies, including GlaxoSmithKline.
" e company is headquartered in Bangalore, 
India, and employs 600.  Its Bangalore site provides 
preclinical and early-clinical R&D services.  A second 
company facility, located in Pune, addresses metabolic 
diseases.
Tata, India’s largest multinational conglomerate, 
recently invested $10 million in Advinus.  
Additionally, Rallis India, a primarily agrochemical 
Tata enterprise, sold its knowledge-services business, 
including drug discovery, to Advinus for USD 6 
million.
Technology capabilities and value-chain 
position
Advinus is engaged in  drug discovery and 
development and in clinical trials.  " e company’s 
capabilities range from identifying precedent drug 
targets to conducting phase II clinical trials.
Advinus specializes in the discovery of 
molecules to target one of three biological areas: 
metabolic disorders (including obesity and asthma); 
in& ammatory diseases (speci$ cally respiratory 
conditions); and neglected diseases (including 
tuberculosis, dengue fever, and malaria).  Advinus 
views its interest in these neglected diseases, which 
are mainly prevalent in third-world nations and not 
$ nancially lucrative to address, as an act of strong 
corporate citizenship.  " e company views India as a 
unique environment in which to $ nd solutions to the 
very diseases that a# ect its population.
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Business model and partnerships
Advinus provides custom pharmaceutical services 
on speci$ c projects and collaborates with outside 
$ rms on research partnerships.  In the long term, 
the company seeks to build revenue through the 
development of original proprietary drug products.  
Dr. Barbhaiya believes that the current western model 
for drug discovery, in which budgets o% en exceed 
a billion dollars to convert a single molecule into a 
viable drug, is not sustainable.  Observing that the 
probability of successfully completing clinical trials 
is greatly increased upon reaching phase III, Advinus 
has developed capabilities to advance drug molecules 
through phase IIB trials.  " e company believes that 
by retaining its molecules for longer and advancing 
their development through high-risk proof-of-
concept clinical trials, it may be able to make higher 
pro$ ts on the sale of future internally developed drug 
candidates.
Advinus’s most notable partnership is with 
Merck. " e research for this partnership focuses 
on two programs to develop drug candidates for 
metabolic diseases.  " e partnership provides 
milestone payments of $74.5 million per target, with 
Advinus being eligible for royalties for any drug 
commercialized.  Advinus will carry out research as 
far as phase II clinical trials, at which point Merck 
retains control through late-stage clinical trials.  
Advinus recently reached its third milestone in this 
arrangement.  It is also conducting collaborative 
research with the DNDi (Drugs for Neglected 
Diseases initiative), a Geneva-based non-pro$ t drug-
development organization.  " e two are cooperating 
to formulate drugs to treat kala azar (visceral 
leishmaniasis), a disease common in India.
Strengths and limitations
Dr. Barbhaiya foresees several limits on 
pharmaceutical growth in India.  Parts of the country 
lack substantive infrastructure to support large-scale 
industry, and the high attrition of talent in many 
pharmaceutical companies limits their capacities to 
expand or maintain projects.  Advinus has been able 
to mitigate the latter by creating a series of innovative 
workforce training and development programs that 
have reduced its annual attrition percentages to single 
digits.
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Business model: original proprietary research; 
multinational division
Active value-chain segments (highlighted in blue):
AstraZeneca China
Company history
AstraZeneca resulted from a merger between Astra 
AB of Sweden and Zeneca Group PLC in 1999.  
AstraZeneca is active in more than 100 countries 
and is increasing its presence in emerging economies 
such as India and China.  " e $ rm employs more 
than 65,000 individuals, just under 3000 of whom are 
located in China.  In 2006, the company’s sales totaled 
USD 26.5 billion, approximately USD 200 million 
dollars of which were made in China.  AstraZeneca 
China is headquartered in Shanghai and has 25 
branches in major cities.  In 2007, the company 
established the Innovation Center China (ICC), to 
focus on translational science, through an investment 
of USD 100 million.  Modeled on an existing R&D 
center in Boston, Massachusetts, this is a discovery 
center with cutting-edge technology.
Technology capabilities and value-chain 
position
AstraZeneca China is active throughout the 
pharmaceutical value chain but focuses on original 
proprietary research and drug manufacture.  " e $ rm 
has established large R&D centers and manufacturing 
facilities, including a USD 170 million manufacturing 
site in Wuxi and the ICC, in Shanghai.  
AstraZeneca China focuses on discovering 
drugs for diseases prevalent in China rather than 
targeting global or western consumers.  Dr. Zhang, 
Head of Innovation, ICC, states that AstraZeneca 
China is di# erentiated from its competitors 
through its guiding philosophy to be “in China, for 
China”.  A large proportion of its R&D spending 
is in six therapy areas: cancer, cardiovascular, 
gastrointestinal, infection, neuroscience, respiratory 
and in& ammation.  " e ICC is currently focusing on 
cancer-related research.
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Business model and partnerships
" e creation of the ICC was a critical element in 
AstraZeneca’s plan to expand its presence in China.  
According to Dr. Zhang, one of the key reasons for 
establishing the ICC was the discovery of di# erential 
response to drugs according to ethnicity.  He also 
added that whereas R&D in the west primarily targets 
lung, breast, prostrate, and colorectal cancer, in 
China, liver and gastric/esophageal cancers are much 
more common.
In dealing with diseases in which it has limited 
in-house expertise, the company has partnered 
with leading medical centers, research labs, and 
universities.  It has collaborative programs and 
strategic partnerships with research institutions and 
hospitals in Beijing, Shanghai, and Guangzhou.
Strengths and limitations
AstraZeneca’s biggest concern is hiring well-quali$ ed 
and well-trained researchers.  About a third of 
the ICC’s researchers (PhDs and postdoctoral 
researchers) have a western education.  " e China-
educated researcherso% en lack practical training in 
drug discovery.  Dr. Zhang added that though change 
in the regulatory environment in China could be 
faster than it is, it is moving in the right direction to 
attract major pharmaceutical companies’ interest.
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Business model: di# erentiated biotech company; 
early-stage drug-discovery collaborations
Active value-chain segments (highlighted in blue):
Aurigene Discovery Technologies
Company history
Aurigene Discovery Technologies (Aurigene), an 
independent subsidiary of Dr. Reddy’s Laboratories, 
was founded in 2001.  " e company provides 
modular discovery services in chemistry and biology 
and describes itself as an early-stage discovery-
collaborations biotech.  It employs 220 scientists 
(110 of whom focus on biology) to perform drug-
discovery research, and it plans to grow to include 
about 300 employees on 15 to 18 discovery programs.  
It has elected not to diversify into drug-development 
work, instead supplying early-discovery services only, 
to a multinational clientele.
Technology capabilities and value-chain 
position
Aurigene’s services are in early discovery and 
re$ nement of novel drugs targeting metabolic 
disorders, cancer, and in& ammation.  Given a 
biological target, it specializes in hit design, hit-to-
lead, lead optimization, and preclinical development.  
O% en, it will evaluate 1000 molecules in this 
cycle.  A% er completing Investigational New Drug 
Application paperwork, Aurigene passes drug-
candidate development to its client.  Aurigene is 
able to conduct many chemical analyses at about a 
quarter of the price of comparable work at a research 
facility in the U.S.  " is is due partly to the lower cost 
of employee salaries: only 50 percent of Aurigene’s 
operating costs, in comparison with up to 90 percent 
of its comparable U.S. competitors’ costs.
Business model and partnerships
Aurigene provides early-research services for major 
pharmaceutical players, including Forest Labs, 
Johnson & Johnson, Orion, Novo Nordisk, Debio, 
MerckSerono, Elan Corporation, and RheoScience.  It 
does not push the boundaries of science, but instead 
provides cost-competitive means to broaden its 
clients’ drug-discovery capacities.  " ese relationships 
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are typically milestone based.  Some of the company’s 
relationships with smaller pharmaceutical $ rms are 
based decreasingly on cost arbitrage and increasingly 
on strategic value.  In these, Aurigene’s ownership 
in the intellectual property it develops increases 
with the amount of early-stage risk it assumes.  " e 
company does not control any of the intellectual 
property associated with its service work for leading 
pharmaceutical companies.
Aurigene’s business structure is unique, in that 
it relies solely on service relationships to remain 
pro$ table.  Few drug-discovery companies are able 
to meet their costs in this way, as its success depends 
heavily on the number, quality, and duration of client 
relationships.
Strengths and limitations
Aurigene de$ nes itself in terms of its business 
relationships, unique service role, and low discovery 
costs. A number of Indian pharmaceutical companies 
have built their businesses on cost-arbitrage strategies 
and are working hard to enter the drug-discovery 
market, but CEO CSN Murthy estimates that these 
companies are several years away from serious 
collaborative relationships with outside $ rms.
Mr. Murthy says it is very di!  cult to hire and 
retain senior-level talent in India.  " is problem has 
been partially alleviated, however, by the increasing 
number of returnees with U.S. training and expertise.
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Business model: generics, APIs, and manufacture
Active value-chain segments (highlighted in blue):
Aurobindo Pharma
Company history
Founded in 1986, Aurobindo Pharma is a vertically 
integrated, R&D-driven company with a broad 
manufacturing portfolio and capabilities.  " e 
company’s 2007 sales were USD 480 million and 
it employs 5000.  In 2001, Aurobindo Pharma 
expanded its operations into the global generics 
market. " e $ rms’ products reach customers in more 
than 100 countries, including established markets 
such as the United States and Europe.  Aurobindo is 
headquartered in Hyderabad, India.
Technology capabilities and value-chain 
position
Aurobindo is primarily involved in the creation of 
active pharmaceutical ingredients (APIs) and $ nished 
generic formulations.  It derives forty percent of 
its revenue from the domestic Indian market.  " e 
export markets, providing the remaining sixty 
percent, include Asia, Africa, Europe, Latin America, 
and the U.S.
Aurobindo Pharma has commercialized more than 
200 APIs and makes $ nished products from some 
of them.  " e company’s cephalosporin antibiotics, 
antivirals, anti-HIV drugs, lifestyle-disease drugs, 
and semi-synthetic penicillin target global markets.  
" e $ rm has more than 120 formulations, targeting 
global markets in seven di# erent therapeutic areas: 
antibiotics (cephalosporins & penicillins); anti-
retrovirals; drugs a# ecting the central nervous system; 
cardiovascular-system drugs; gastroenterologicals; 
anti-diabetics; and anti-allergics.
When Aurobindo’s team identi$ es a promising 
drug alternative, it conducts an internal 
bioequivalence study.  Aurobindo concentrates on 
research that makes sense to its customers, which are 
(the generics market aside) largely companies that 
buy APIs and intermediaries.  It also o# ers chemical 
development and custom synthesis.  
Aurobindo has gradually expanded its capabilities 
beyond API manufacturing.  " e company’s in-house 
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R&D team now has expertise in chiral synthesis, 
column technology, complex chemistry, fermentation, 
sterile manufacture, and other processes.  Aurobindo 
states that it now produces its own intermediaries and 
formulations, a% er directly acquiring raw materials.
Business model and partnerships
Aurobindo’s APIs are sold to customers who in 
turn use them in their own drug formulations 
and manufacture.  In the four years prior to 2008, 
Aurobindo has made initial forays into the U.S. 
and European markets and is currently working to 
expand its distribution networks in these countries.  
Due to high entry barriers in regulated markets, 
Aurobindo $ rst sold its APIs to companies in Latin 
America, Africa, and the Asia–Paci$ c.  " is allowed 
it to establish a network and gain a foothold in less-
regulated markets.
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Business model: original proprietary research; 
research partner; generics, APIs, and manufacture
Active value-chain segments (highlighted in blue):
Biocon
Company history
Biocon was founded in 1978 by its current chairman 
and managing director, Ms. Kiran Mazumdar-Shaw.  
Its headquarters are in Bangalore, India, and the 
company employs 3000.  In 2007, its sales revenue 
was USD 219 million.
Technology capabilities and value-chain 
position
Biocon’s products target diabetes, cancer, and 
in& ammatory diseases.  " e company has three 
subsidiary companies: Syngene International 
Ltd, Clinigene International Ltd, and Biocon 
Biopharmaceuticals Private Ltd.
Syngene conducts custom drug-discovery 
research.  It o# ers synthetic-chemistry and molecular-
biology services for early-stage drug discovery and 
development.  Its core strengths include chemistry 
and biology services.
Clinigene conducts preclinical development 
activities; clinical-data management and biostatistics 
for phase 0 clinical trials; and regulatory services for 
phase II and phase III clinical trials.  " e subsidiary 
undertakes this work using a human-pharmacology 
unit, bioanalytical-research laboratory, and central 
laboratory.  " ese facilities are used to conduct in-
vivo and in-vitro testing on both laboratory animals 
and human patients.  Once a drug candidate has 
passed through phase III clinical trials, the project is 
passed to Biocon Pharmaceuticals.
Biocon Biopharmaceuticals focuses on product 
commercialization and manufacture.  It is responsible 
for research collaboration, product development, 
manufacturing, regulatory $ ling, marketing, custom 
manufacturing, and licensing.
Biocon also actively produces generic molecules 
and active ingredients for sale to other pharmaceutical 
$ rms, as well as consumer drugs for sale in more than 
70 countries.  " e $ rm’s manufacturing capabilities 
have grown from enzyme production to recombinant 
protein assembly and antibody production.  Its 
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drug portfolio includes Insugen, a brand of insulin; 
BIOMab EGFR, the $ rst anticancer drug in India; 
and monoclonal antibodies and therapeutic proteins.  
Biocon also produces an extensive array of APIs, 
including anti-diabetic agents, anti-in& ammatories, 
antioxidants, and nutraceuticals.
Business model and partnerships
In addition to its original proprietary research and 
manufacture of generics and APIs, Biocon o# ers 
custom manufacturing and research services.  Its 
partners include Bristol–Myers Squibb, which has 
been a customer since 1998.  Bristol–Myers Squibb 
increased the breadth of its relationship with Biocon 
in 2007 through a partnership with Syngene.  As part 
of this relationship, Syngene will allocate more than 
400 employees to focus on early drug development for 
Bristol–Myers Squibb.
" e majority of Biocon’s drug discovery and 
development; clinical trials; and manufacturing 
activities are internal, although the $ rm occasionally 
partners with other $ rms.  " e company also provides 
custom research services. 
Syngene o# ers full-time–equivalent programs, in 
which the company provides its client with a project 
team for a speci$ ed period at a $ xed rate.  It also 
earns milestone payments and enters into risk-sharing 
ventures. 
Strengths and limitations
According to Mr. Rakesh Bamzai, Biocon’s Head of 
Marketing, the depreciating dollar is a major concern, 
as 65 percent of the $ rm’s revenues come from sales in 
international markets.  Biocon’s range of capabilities, 
however, provides it with multiple revenue 
streams, allowing the company to balance risk and 
accelerate growth, he states.  Competition within 
highly regulated markets is contributing additional 
pressures.
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Business model: generics, APIs, and manufacture
Active value-chain segments (highlighted in blue):
Cipla
Company history
Cipla (Chemical, Industrial and Pharmaceutical 
Laboratories) was established in 1935 and 
has revenues of over USD 1 billion.  Cipla is 
headquartered In Mumbai, India, and employs 
around 2200 individuals.
Prior to the 2005 amendment of the Indian Patent 
Act of 1972, the Indian government enforced patents 
on processes only.  During this time, Cipla operated 
within these laws to develop and manufacture a 
range of generics and APIs for sale and distribution 
in markets not regulated by product patents.  Cipla 
also contributed to humanitarian e# orts in Africa 
by providing anti-AIDS medication for about USD 
300 per patient per year, one-fortieth to one-$ % ieth 
of the cost of MNCs’ competing treatments.  (Please 
consult the earlier discussion “Storm over intellectual 
property” for additional crucial background on Cipla, 
Yusuf Hamied, and the company’s founding family).
Technology capabilities and value-chain 
position
Cipla operates within the generics, APIs, and 
manufacture segments of the pharmaceutical value 
chain.  " e company produces drugs to treat a 
variety of conditions, including AIDS, cardiovascular 
diseases, diabetes, and depression.  " ese products 
are distributed to ~180 countries, including highly 
regulated U.S. and European markets.  Cipla also 
manufactures pharmaceutical ingredients, drug 
intermediates, and generics that are consumed by 
international organizations and businesses, including 
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Big Pharma.  " e $ rm’s manufacturing facilities have 
received regulatory approval in the U.S., the U.K, 
Australia, Africa, Hungary, Germany, Canada, and 
Brazil.
Business model and partnerships
" e company markets its own products world wide. 
It is able to o# er its competitive generics pricing 
through international disclosure of drug data and its 
manufacture of its own drug intermediaries. 
Strengths and limitations
Cipla’s CEO, Dr. Yusuf Hamied, commented that 
competition within established drug markets is being 
hampered by drug “evergreening”: extended patent 
protection on lucrative pharmaceutical drugs through 
incremental patent changes as expiration approaches.  
He explained that this is o% en accomplished by 
mixing drugs, changing delivery mechanisms, or 
altering the target condition a drug treats.
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Business model: original proprietary research; 
generics, APIs, and manufacture
Active value-chain segments (highlighted in blue):
Dabur Pharma
Company history
Dabur Pharma, based in New Delhi, India, is 
an associate company of Dabur India limited, a 
healthcare corporation founded in 1884.  Dabur 
Pharma was incorporated in 2003 and employs 1000 
individuals, 200 of whom are directly engaged in 
R&D.  In 2007, it produced sales of USD 77 million.  
In April 2008, the German healthcare company 
Fresenius Kabi acquired Dabur Pharma for USD 
219 million, an unusually large pharmaceutical 
acquisition by a foreign company, in order to expand 
its drug portfolio and its API-production capabilities.
Technology capabilities and value-chain 
position
Dabur Pharma is involved in the development and 
manufacture of generics and APIs to treat oncology 
conditions, and to a lesser degree in the discovery 
and development of early-stage proprietary drugs.  As 
a manufacturer of generic drugs, the company has 
seven Abbreviated New Drug Applications $ led with 
the U.S. FDA.  It manufactures drugs for commercial 
use through its facilities in India and the U.K.  Its 
portfolio also includes more than 45 oncology-related 
APIs and $ nished-dosage forms.  Its research occurs 
primarily through the Dabur Research Foundation, 
an independent research organization established in 
1979.  " e foundation has $ led more than 130 patent 
applications, of which 40 have been granted.
Until 2007, Dabur Pharma developed and 
marketed products in “less-regulated markets” such as 
India, the Asia–Paci$ c, the Middle East, and Africa.  
It entered the European and U.S. markets in 2007 and 
hopes to introduce 25 drugs in the U.S. in the next 
three to $ ve years.
Dabur Pharma invests 10 to 12 percent of its R&D 
budget in new-concept drugs and drug-delivery 
systems.  One of its successes is Nanoxel, the $ rst 
nanoparticle drug-delivery system developed outside 
the U.S.  " e company released Nanoxel in India 
in 2007, a% er receiving approval from the Drug 
35
The Globalization of Innovation: Pharmaceuticals
Controller General of India (DCGI), India’s drug-
regulatory body.
Business model and partnerships
Dabur Pharma develops proprietary products until 
the preclinical testing phase.  It then seeks to license 
its technology or form a partnership with a major 
multinational company in order to advance the 
compound through the risk- and cost-intensive 
clinical-trial phase.  " is business is complemented by 
Dabur Pharma’s $ nished-dosage and API products, 
which are distributed to select Asian, European, 
African, and Latin American markets.
" e company had an agreement with Abbott 
Labs in the U.S.  to provide Abbott Labs’s Hospital 
Products Division with $ nished-dosage forms of 
generic oncology products.  " e companies shared 
development, marketing costs, and pro$ ts.  Dabur 
Pharma says itended this partnership in order to 
employ its subsidiary, Dabur Pharma U.S., for sales 
and distribution of its products in the United States.
Strengths and limitations
Dabur Pharma sees its vertical integration and 
specialization in oncology (unusual in Indian 
pharmaceutical $ rms) as a competitive advantage.
" e high rate of attrition in the Indian 
pharmaceutical industry is a signi$ cant challenge to 
Dabur Pharma’s ability to retain personnel who have 
received expensive in-house training.
With the number of global $ rms entering 
specialized $ elds such as oncology, price competition 
is another major challenge.
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Business model: original proprietary research; 
contract research organization; generics, APIs, and 
manufacture
Active value-chain segments (highlighted in blue):
Dr. Reddy’s Laboratories
Company history
Established in 1984, Dr. Reddy’s Laboratories was an 
early entrant in and remains a signi$ cant player in 
India’s pharmaceutical industry.  In the late 1980s, 
the $ rm entered the bulk-generics market by reverse-
engineering foreign drugs and devising new means 
of mass-manufacturing generic alternatives at costs 
attractive to the Indian market.  In 1992, Dr. Reddy’s 
began conducting drug-discovery research.  Today 
the $ rm has ~9000 employees.  In 2007, it generated 
sales of more than USD 1.44 billion.
Dr. Reddy’s is listed on the New York Stock 
Exchange.
Technology capabilities and value-chain 
position
In addition to developing generic products, Dr. 
Reddy’s is actively engaged in a variety of drug-
discovery programs.  Its short- and medium-term 
investments are in the creation of generics and 
APIs and the provision of custom pharmaceutical 
services for Big Pharma.  Dr. Reddy’s generics 
business markets more than 150 brands of $ nished 
dosages, and it releases 15 to 20 new products 
annually, including gastrointestinal, antimicrobial, 
cardiovascular, dental, dermatological, diabetes, pain-
management, and urological drugs.
Dr. Reddy’s API business includes commercialized 
products in 25 regulated markets and more than a 
hundred products in near-regulated markets.  " ese 
APIs are produced using seven FDA-approved plants 
in India and Mexico and are distributed to more than 
800 customers in 100 countries, including top-tier 
global and regional generics companies.  Dr. Reddy’s 
also o# ers custom pharmaceutical services to various 
customers, including emerging companies and 
more than $ ve major pharmaceutical players.  " ese 
services include drug-discovery and -development 
and manufacture, and o% en use Dr. Reddy’s R&D 
facilities, organic-chemistry expertise, or analytical 
capabilities.
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Medium- to long-term revenue comes from drug-
discovery research, specialty pharmaceuticals, and 
biologics (also called bio-similars).  Dr. Reddy’s 
drug-discovery research involves the collective e# orts 
of ~300 chemists and engineers and 21 organic-
chemistry laboratories located in research centers in 
Hyderabad, India, and in Atlanta, Georgia.  " ese 
groups focus on cardiovascular and metabolic 
disorders; oncology; and bacterial infections, and they 
develop potential drugs through in-house research 
and partnerships.  Dr. Reddy’s is also engaged in 
the development of special pharmaceuticals and 
biologics — innovation-based, di# erentiated product 
development focusing on the creation of new 
biological entities and second-generation variant 
biologics — targeting the North American and 
European markets.
Business model and partnerships
Dr. Reddy’s follows a variety of business models, 
including the manufacture and sale of generics, 
APIs, and branded $ nished dosages; partnerships 
and custom pharmaceutical services with major 
pharmaceutical players; and original drug-
development programs. " e company’s goal is to 
take candidate drugs through phase IIa clinical trials 
and then seek licensing agreements, commercial 
partnerships, or customers for the drug’s intellectual 
property.
Strengths and limitations
One of Dr. Reddy’s strengths is control over its supply 
chain.  Control over critical capabilities — process 
development, API-dossier submission, patent 
expertise, and manufacture — has allowed it to 
achieve cost-e# ective and high-speed development of 
bulk generics and APIs.
Dr. Reddy’s has also achieved signi$ cant cost 
savings on certain drug-development activities.  In 
some projects, the company says, preclinical trials 
can be completed for 40 to 60 percent less than 
the traditional research costs of a multinational 
corporation.  " ese cost reductions result from in-
place processes and lower cost bases.  Conducting 
toxicology work in house has enabled cost savings of 
about 50 percent.
Dr. Reddy’s states that its employee retention is 
well above industry average, and it has been able to 
grow its business through the acquisition of U.S.-
trained talent.  In the last few years, Dr. Reddy’s 
has been very successful at acquiring personnel, 
most o% en Indian-born foreign nationals, from 
U.S. pharmaceutical R&D centers in the throes of 
closure.  Individuals unwilling to relocate to India can 
sometimes be accommodated in Dr. Reddy’s Atlanta 
facility.
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Business model: original proprietary research; 
research partner
Active value-chain segments (highlighted in blue):
Hutchison MediPharma
Company history
Hutchison MediPharma, located in Shanghai, China 
was founded in 2002 as a pharmaceutical research and 
development $ rm.  It is a wholly owned subsidiary 
of Hutchison China Meditech Ltd (Chi–Med), 
which is in turn 72 percent owned by Hutchison 
Whampoa Limited, an international corporation with 
diverse holdings that include a number of healthcare 
$ rms (Hutchison Baiyunshan; Shanghai Hutchison 
Pharmaceuticals; and Hutchison Healthcare). In 
2007, Chi–Med provided USD 10 million in funding 
to cover the costs of discovery programs and clinical 
trials in the U.S. and China. " e company has 200 
employees. 
Technology capabilities and value-chain 
position
Hutchison MediPharma focuses on precedented 
pharmaceutical targets and is active in all stages 
of drug discovery.  Candidate drugs are developed 
through phase II clinical trials.  " e $ rm owns 
and operates a research and development facility 
in Shanghai’s Zhang Jiang High-Tech Park and 
a Chinese-certi$ ed animal testing facility.  Its 
discovery-chemistry strategy is based on new 
botanical drugs, semi-synthetic natural-product 
drugs, and synthetic compounds.  It is currently 
performing clinical trials in the U.S. on several drugs 
with established proof of concept in China.  Its two 
most promising, which have received FDA approval 
for phase I and phase II clinical trials in the U.S., 
are HMPL-002, a radiosensitiser for the treatment 
of head, neck, and non–small-cell lung cancers in 
combination with chemo and radiotherapy; and 
HMPL-004, a proin& ammatory-cytokine inhibitor for 
the treatment of Crohn’s disease and ulcerative colitis.
Business model and partnerships
Hutchison MediPharma focuses on the development 
of drugs to treat cancer and autoimmune diseases.  
Revenue for the company is generated via risk-and-
39
The Globalization of Innovation: Pharmaceuticals
reward sharing in research (obtaining revenue from 
milestone payments as well as from royalties on drug 
sales) and by licensing its own drug products once 
they have reached the latter stages of development 
prior to phase III clinical trials.
" e company has partnered with Eli Lilly, Merck 
KGaA (Germany), and Procter & Gamble.  It also has 
several alliances with academic institutions, including 
the University of California at Los Angeles, Shanghai 
Institute of Materia Medica, the Genetic and Cell 
Biology Institute of North-Eastern Normal University, 
Hong Kong Chinese University, the University of 
Maryland, and Cambridge University.  " e $ rm 
engages these academic institutions in an e# ort to 
identify novel drug targets and build compound 
libraries.
Strengths and limitations
Hutchison MediPharma is one of the few domestic 
Chinese companies with a fully integrated drug-
discovery and -development infrastructure.  " e $ rm 
believes it has an advantage in its ability to move 
drugs along the value chain quickly and e!  ciently 
by taking advantage of the Chinese clinical-trial 
regulatory environment for faster proof-of-concept 
studies, shorter patient-recruitment times, and lower 
patient costs than are possible in the U.S. 
Most of Hutchison MediPharma’s scientists are 
western-trained.  " e management team consists 
of former research executives of international 
pharmaceutical and biotechnology companies.
Hutchison MediPharma’s CEO, Dr. Du, believes 
that improvements in the Chinese regulatory 
environment may provide her company with further 
advantages.  China has only recently been exploited as 
a venue for global pharmaceutical-drug discovery and 
development, she says, and the laws and regulations 
have not yet adapted to this explosion of growth.  
She also believes that there is a bottleneck between 
research and development activities in China that 
modern regulations could alleviate, in terms both of 
the long approval time for the State Food and Drug 
Administration (SFDA) of China to allow for clinical 
trials and of the amount of preclinical data required 
in order to start clinical trials.
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Business model: original Proprietary research; 
research partner; generics and manufacture
Active value-chain segments (highlighted in blue):
Novartis China
Company history
Novartis was founded in 1996 through the merger 
of prominent Swiss chemical and life-sciences 
companies Ciba–Geigy and Sandoz.  In the twelve 
years since, Novartis has established itself as a 
prominent global pharmaceutical company with sales 
in more than 140 countries, annual revenue of USD 
39 billion, and 98,000 employees world wide.
Novartis $ rst established a Beijing o!  ce in 
1997.  Today, the company employs more than 2000 
individuals in China.  By 2007, China revenues had 
reached USD 342 million.  With the Chinese market’s 
projected growth, establishing a foothold in the 
country is a top priority for Novartis.
Technology capabilities and value-chain 
position
In China, Novartis is engaged in the discovery and 
development of proprietary-drug candidates and 
the manufacture and sale of generic drugs.  It is 
building capabilities to pursue drug development 
through phase III clinical trials.  Dr. Kevin Chen, 
Chief Operating O!  cer of Novartis Institutes for 
Biomedical Research in Shanghai, says that his 
company’s focus has been on drugs for diseases 
that are prominent in the Chinese and Asian 
populations, such as infectious diseases and liver 
cancer.  It is building a USD 100 million R&D center 
in Shanghai and an USD 83 million manufacturing 
and development center in Changshu to address these 
opportunities.
Business model and partnerships
Novartis China is actively pursuing projects aimed 
at the Chinese market.  " e company’s internal R&D 
e# orts are complemented by its collaborative e# orts 
and partnerships with Fudan University, Shanghai 
Institute Materia Medica, and WuXi PharmaTech, 
amongst others.  " ese collaborations are based 
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on knowledge sharing and information exchange 
to promote innovation, technology, and new-drug 
discovery.
Strengths and limitations
Having identi$ ed the immense growth potential in 
China, Novartis aspires to establish Novartis Institutes 
for Biomedical Research in Shanghai as a leading 
R&D center.  According to Dr. Chen, some of the key 
challenges that Novartis faces in achieving its business 
goals are the ability to recruit and retain well-trained 
people and, as a global organization, to manage the 
cultural and geographic di# erences between East 
and West.  Despite the availability of many Chinese 
graduates, there is still a shortage of highly skilled 
managers and experienced, well-trained researchers.  
Novartis is meeting the demand for skilled personnel 
by hiring western-educated Chinese returning to 
China in search of better opportunities. Seventy 
percent of managers and 30 to 40 percent of R&D 
sta#  members hold degrees awarded outside China.
Other key concerns include an English–Chinese 
language barrier; the timely availability of reagents; 
and regulatory constraints.
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Business model: original proprietary research; 
manufacturing
Active value-chain segments (highlighted in blue):
P zer (China)
Company history
Founded in 1849 and headquartered in New York, 
U.S., P$ zer Inc. is the world’s largest pharmaceutical 
$ rm by market share, controlling 6.3 percent of the 
global pharmaceutical market in 2007.  " e $ rm has 
85,000 employees located in more than 150 countries, 
and its 2007 revenues were USD 48.4 billion.  Its R&D 
spending in 2007 was USD 8.1 billion.  P$ zer has 
grown signi$ cantly in the last two decades, largely 
through mergers and acquisitions; the $ rm was the 
14th-largest pharmaceutical company in 1990.  
P$ zer has been operating in China since the 
early 1980s.  P$ zer (China) employs about 2500 
individuals, of whom 200 focus on research and 
development (R&D).  " e company has invested 
more than USD 500 million in its China operation, 
which includes a presence in more than 160 cities 
and state-of-the-art pharmaceutical plants in Suzhou, 
Dalian, and Wuxi.  Its R&D center in Shanghai is a 
part of P$ zer Global Research & Development.
Technology capabilities and value-chain 
position
P$ zer is actively involved in discovery, development, 
clinical trials, and manufacture.  Its operation in 
China engages in sales and marketing; manufacturing; 
and R&D through partnerships with contract research 
organizations (CROs) and local academic research 
institutions.  It also conducts clinical trials supporting 
its local and global drug development.
Business model and partnerships
P$ zer is increasingly relying on acquisitions and 
CROs to $ ll the company’s drug-development 
requirements.  About 50 percent of these needs 
are $ lled through acquisitions.  Concerned for 
its intellectual property, P$ zer has built trusted 
relationships with only a few companies and has 
avoided collaborations involving its most sensitive 
intellectual property.  It is now using its CRO partners 
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for more of the complex work, though.  One such 
is WuXi PharmaTech, one of China’s largest CROs, 
which P$ zer contracts to perform lab services and 
custom synthesis work.  
Dr. Steve Yang, Vice-President and Head of Asia 
R&D, states that the majority of Chinese CROs 
o# er R&D services that are functionally based (e.g. 
chemistry, biology, etc.) and that more Indian CROs 
o# er integrated services.  Despite this, Dr. Yang 
expects the majority of innovation in the near future 
to originate in the U.S. and Western Europe, given 
the substantial scienti$ c-research ideas and expertise 
that both regions have accumulated in academia and 
industry in the past several decades.
In Asia, P$ zer has yet to negotiate any risk-sharing 
relationships with outside $ rms and continues to 
rely exclusively on acquisitions and CROs for drug-
discovery.  In addition, P$ zer’s Shanghai R&D 
center, with about 200 employees, supports P$ zer’s 
global clinical development.  P$ zer plans signi$ cant 
expansion of R&D, especially in oncology and in 
types of disease common in Asia.
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Business model: original proprietary research; 
research partner; generics, APIs, and manufacture
Active value-chain segments (highlighted in blue):
Ranbaxy Laboratories
Company history
India’s largest pharmaceutical company, Ranbaxy 
Laboratories (Ranbaxy), is a sizable contributor to 
the global production of generic drugs.  Incorporated 
in 1961, it employs more than 12,000 individuals, 
including more than 1400 are scientists engaged 
in research and development (R&D).  Its revenue 
was USD 1.6 billion in 2007, of which USD 419 
million came from North America and USD 365 
from Europe.  Approximately seven percent of the 
company’s revenue was spent on R&D in 2007.
Ranbaxy sells products in 125 nations, in 11 of 
which it has manufacturing facilities.  With signi$ cant 
experience in the manufacture and distribution of 
generics, the company is now actively engaged in 
expanding its high-value capabilities.
Technology capabilities and value-chain 
position
Ranbaxy designs and manufactures generic drugs, 
APIs, and pharmaceutical intermediaries; conducts 
internal research on new drug-discovery and 
drug-delivery systems; and is collaborating with 
GlaxoSmithKline and Merck on preclinical testing.
" e company’s generic drugs target infectious, 
cardiovascular, central nervous system, respiratory, 
dermatological, orthopedic, nutritional, and 
urological conditions.  Ranbaxy is also developing 
ten new chemical entities for use in infectious 
diseases, urology, metabolic disease, oncology, 
and in& ammatory and respiratory illness.  " e 
company innovates in its generics business through 
an understanding of high-yield generics chemistry 
and the creation of $ xed-dose drug combinations, 
combining multiple treatments in a single pill.  
Business model and partnerships
Ranbaxy’s business strategies include the internal 
development, manufacture, and distribution of 
generic drugs; partnerships with outside $ rms; and 
corporate acquisitions. It enhanced its portfolio of 
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products by establishing joint ventures and acquiring 
companies in Europe, Africa, and the U.S..  
It is collaborating with GlaxoSmithKline (GSK) to 
investigate a range of therapeutics of interest to GSK, 
including anti-infectives and metabolic, respiratory, 
and oncology products.  A joint Ranbaxy–GSK 
team recently approved the candidate selection of 
a respiratory-in& ammation target, and in February 
2007 Ranbaxy signed an agreement with GSK 
enlarging its development responsibilities.  GSK 
presented Ranbaxy with a series of target compounds 
prescreened for suitability in high-volume 
manufacture.  Ranbaxy’s role is to perform toxicity, 
selectivity, enzyme-regulation, and inhibition studies 
on these targets.  A recently signed agreement with 
Merck gives Ranbaxy responsibility for discovery 
and development through phase IIa clinical trials of 
several potential antimicrobials.  Milestone payments 
for each collaboration may total more than USD 100 
million, and Ranbaxy will be eligible for royalties 
from both.  Alliance and partnership have enabled the 
company to enter new specialty therapeutic segments, 
including bisimilars, peptides, and limuses (anti-
arteriosclerotic drugs).
Strengths and limitations
Ranbaxy’s Executive Director, Ramesh Adige, 
believes that the strength of India’s bench chemists 
combines with labor-cost e!  ciency to create a 
unique environment.  Moving up the value chain 
into activities that are more lucrative requires greater 
investment in R&D, which his company is now 
making.  Senior Vice-President (New Drug Discovery 
Research), Pradip Bhatnagar, acknowledges that 
foreign companies are o% en hesitant to hand over 
proprietary manufacturing processes or disease-
related biomarkers, as these core pieces of intellectual 
property are instrumental in de$ ning manufacturing 
practices and early-stage research respectively. He 
believes this caution is now changing.
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Business model: contract research organization
Active value-chain segments (highlighted in blue):
ShanghaiBio
Company history
ShanghaiBio is the CRO subsidiary of Shanghai 
Biochip Co., Ltd, which was established in 2001 
through funding from seed investors and the Chinese 
government.  " e company is located in Shanghai’s 
Zhangjiang Medicine Valley and has a global business 
o!  ce in New Jersey, U.S.  It employs 300.
In addition to performing contract research, 
ShanghaiBio has engaged in various academic 
biology-research endeavors.  " e $ rm also 
contributed to one percent of the human genome 
sequencing project and in ten percent of the Human 
Genome HapMap project.
Technology capabilities and value-chain 
position
ShanghaiBio has positioned itself as a provider of 
biological, preclinical, and clinical-trial services 
throughout the value chain.  It o# ers a range of 
systems-biology tools and resources to enable its 
clients to target and analyze biological pathways and 
preclinical and clinical biomarkers.  " ese include 
genomics, proteomics (study of the proteins that an 
organism produces), pharmacogenomics (study of 
the in& uence of genetic variation on drug response), 
target-validation techniques, bioinformatics, 
global logistics of clinical samples, and tissue 
banks.  Shangahi Bio was the $ rst Chinese service 
provider authorized to use A# ymetrix GeneChips, a 
leading microarray technology widely employed in 
microarray studies, which analyze gene expression 
from many genes simultaneously, and it has analyzed 
tens of thousands of these gene chips in performing 
data analysis and sample processing for its clients.  
" e company has a tissue bank containing 
more than 10,000 samples with detailed clinical 
information.  It provides preclinical trial services and 
support in phase I to phase IV clinical trials.  " e 
company has access to hospitals and to small and 
large laboratory animals and the neighboring service 
partners from which to obtain them.  It conducts 
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drug-e!  cacy testing, pharmacokinetic analyses, and 
biomarker validations.
Business model and partnerships
ShanghaiBio receives $ xed payments for its biology 
and research services, according to the type and 
complexity.  In 2007, ShanghaiBio’s work portfolio 
included 22 international projects with major 
pharmaceutical $ rms.  Example clients include 
Merck, GlaxoSmithKline, Johnson & Johnson, and 
Lilly.  Merck contracted ShanghaiBio for a long-
term collaboration on a clinical oncology study.  
ShanghaiBio collected tissue samples indicative of 
four types of oncology for use in clinical trials; used 
its microarray expertise to analyze gene expression; 
and presented the $ nal gene panels, unanalyzed, 
to Merck, allowing Merck to maintain exclusive 
control over the intellectual property arising from 
its research.  For Johnson & Johnson, ShanghaiBio 
provided a genotyping SNP analysis of metabolism 
genes obtained from clinical samples in many 
countries.  
ShanghaiBio states that it was able to collect 100 
specialty biosamples for Lilly during a three-week 
period in China that were nearly impossible to obtain 
in the U.S.
Strengths and limitations
ShanghaiBio says it is able to provide its clients 
with timely and cost-e# ective services, achieving 
these savings through its possession of a signi$ cant 
proprietary tissue and blood bank; the relative 
ease of new-tissue acquisition in China; strong 
internal technology capabilities; dedicated project 
management; and quality control.  On many projects, 
it is able to o# er prices 30 to 60 percent lower than 
U.S. pricing, and sample-collection costs can be 
discounted by as much as 90 percent.
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Business model: contract research organization
Active value-chain segments (highlighted in blue):
Shanghai ChemPartner
Company history
Shanghai ChemPartner, a contract research 
organization (CRO), was founded in 2003 as the 
& agship subsidiary of ShangPharma, China’s second-
largest pharmaceutical and biotechnology CRO.  As 
of 2008, it has about 1200 employees, 15% of whom 
hold PhD degrees. 
In November 2007, the company received a 
strategic investment from Texas Paci$ c Group, 
a private investment partner, to integrate drug-
discovery and -development processes.
Technology capabilities and value-chain 
position
Shanghai ChemPartner provides project-speci$ c 
R&D capabilities in the $ elds of pharmaceuticals, 
biotechnology, agrochemistry, and chemistry.  
It operates a state-of-the-art R&D laboratory, 
including 800 synthetic workstations, in Shanghai’s 
Zhang Jiang Hi-Tech Park.  It is active in all stages 
of drug discovery and development, beginning 
with compound generation.  " e $ rm is o% en 
engaged to perform biological-target validation, 
assay development, hit-to-lead optimization, and 
preclinical development.  " e company performs 
no clinical trials but is involved in preclinical 
development, and its services include discovery 
chemistry; library generation; analytical chemistry; 
medicinal chemistry; process chemistry; absorption, 
distribution, metabolism, and excretion (ADME) 
studies; natural-product chemistry; computational 
chemistry; and drug design.  As a CRO, Shanghai 
ChemPartner does not specialize in any disease area 
but tailors its services to customer requirements.
Business model and partnerships
Shanghai ChemPartner performs custom research 
services within the drug discovery and pre-clinical 
trials portions of the pharmaceutical value chain.  Its  
clients include Curis Inc. and LEAD " erapeutics.
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Strengths and limitations
Shanghai ChemPartner’s Vice-President of 
Biology, Dr. Xu, believes that three factors give 
the company a competitive advantage over its 
American CRO counterparts: speed, quality, and 
cost.  " e management sta#  is western-educated, 
and the majority received U.S. degrees.  About 50 
management and scienti$ c leaders have western 
degrees or work experience.
Dr. Xu sees several hurdles to future growth of 
the pharmaceutical industry.  First, the cost of labor 
is rising, and competition for top talent is becoming 
$ ercer.  Second, the company is $ nding di!  culty 
in the import and export of biological samples and 
reagents to and from China.  Finally, regulatory 
restraints limiting the acceptance of new-drug 
applications and the creation of new clinical trials 
remain to be overcome.
Dr. Xu also believes that westernizing the Chinese 
pharmaceutical industry will be necessary to attract 
western multinational business.  " e industry is in 
a state of rapid change, vigorously broadening its 
product range and abbreviating the cost and time of 
drug discovery and development. 
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Business model: generics, APIs, and manufacture
Active value-chain segments (highlighted in blue):
Sun Pharmaceutical
Company history
Sun Pharmaceutical Industries Limited, located in 
Mumbai, India, was founded in 1983.  It began with 
$ ve products that treated psychiatric ailments, and 
these were sold in only two states in India.  As of 
2008, Sun Pharmaceutical employs more than 7000 
, on three continents, and has 17 manufacturing 
units and two research sites.  Its revenues in the year 
to March 2008 were USD 800 million, of which 43 
percent came from $ nished dosages sold in India and 
41 percent came from generics sold in the U.S.
Technology capabilities and value-chain 
position
Sun Pharmaceutical develops specialty APIs and 
formulations targeting niche segments of the Indian 
pharmaceutical market, including drugs to treat 
cardiovascular, gastroenterological, psychiatric, 
and neurological disorders.  " e $ rm has two R&D 
centers, which house more than 550 scientists, and its 
facilities include stability-testing labs, nanotechnology 
labs, liposome labs, and an aerosol area.  Ten percent 
of the company’s net sales is spent on generic-drug 
research and development.  " e company has been 
awarded 70 patents on technology developed through 
its research endeavors.
Sun Pharmaceutical also has 17 manufacturing 
facilities, seven of which (six in India and one in 
Hungary) are devoted to the production of APIs 
and are ISO 14001– and ISO 9002–approved.  " e 
company o# ers more than 150 APIs, the majority 
of which have been approved for distribution in 
regulated markets, including Europe and the U.S.
Sun Pharmaceutical has a number of subsidiaries, 
most of which it acquired.  Caraco is its U.S. generics 
subsidiary.  Sun Pharmaceutical’s acquisition of M.J. 
Pharmaceuticals, whose plants are approved for the 
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manufacture of products in South Africa, Brazil, and 
Columbia, enabled it to progress in international 
markets.  Acquisition of ICN Hungary in 2005 
enabled it to enter the controlled-substance API-
manufacturing market.  A merger with Tamil Nadu 
Dadha Pharmaceuticals provided capabilities in 
fertility, cancer, anesthesiology, gynecology, and pain 
management.
Business model and partnerships
Sun Pharmaceutical has relationships with several 
Indian, Chinese, and European companies that supply 
it with pharmaceutical ingredients.  Within the U.S., 
it distributes products through Wal-Mart, Walgreens, 
CVS, Cardinal, and others.
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Business model: contract research organization
Active value-chain segments (highlighted in blue):
WuXi PharmaTech
Company history
WuXi PharmaTech was founded in 2000 as a 
pharmaceutical and biotechnology contract research 
organization (CRO).  It currently has 3300 scienti$ c 
sta#  members, including 2550 scientists, and provides 
integrated services in drug research and development 
(R&D), clinical trials, and manufacture.  " e 
company has more than 700 customers, including 
major pharmaceutical, biotechnology, and medical-
device companies in the U.S., Europe, and Japan.  In 
2007, WuXi PharmaTech earned USD 33.9 million 
on revenues of USD135.2 million.  In January 2008, 
it acquired AppTec Laboratory Services, a U.S.-based 
company.  Company o!  cials state that they expect 
this acquisition to help double revenues in 2008.
Technology capabilities and value-chain 
position
WuXi PharmaTech specializes in laboratory services, 
preclinical development, and manufacture.  Its 
laboratory services include lead generation; lead 
optimization; synthetic chemistry; assay development; 
drug metabolism and pharmacokinetics; absorption, 
distribution, and excretion; metabolite identi$ cation; 
animal-disease modeling; and toxicology services.  
Its pharmaceutical-development services consist 
of preformulation studies, analytical development, 
stability evaluation, and regulatory-submission–
preparation services.  It is one of the few originally 
Chinese companies with these laboratory and 
developmental capabilities that also manufacture 
drugs. 
WuXi PharmaTech operates a large research 
facility in Shanghai Waigaoqiao Free Trade Zone; 
a cGMP-quality manufacturing plant in Jinshan 
District, Shanghai; and a new Tianjin research 
facility.  It is constructing in Suzhou what is routinely 
called China’s largest preclinical drug-safety center, a 
building 323,000 square feet (30,000 square metres) in 
& oor area.
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Business model and partnerships
WuXi PharmaTech says it plans to remain a service 
company.  It has a passion for researching possible 
compounds for new-concept drugs, but no interest in 
the $ nancial risks associated with the low success rate 
of candidate drugs.
WuXi PharmaTech does not specialize in any 
disease area, but instead tailors its service to its 
customers’ requirements.  Similarly, using the CRO 
model, it assumes none of the $ nancial risks, positive 
or negative, involved in pharmaceutical R&D, and 
disowns all interest in the intellectual property 
created in the collaboration.  About 80 percent of its 
revenue comes from relationships with American 
companies; 15 percent from European; and $ ve 
percent from Japanese.  Its partners include Merck, 
P$ zer, and others.  When it was $ rst established, 
most of its customer relationships were transactional 
and tactical, but the company says its relationships 
with partnering $ rms are becoming strategic and 
long-term.  In the majority of drug-development 
relationships, WuXi PharmaTech is contracted to 
create molecules and to prepare them for clinical 
trials.
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Appendix A: Glossary
Active Pharmaceutical Ingredients (APIs): the intermediate chemicals and compounds used in the manufacture of 
$ nal drug products.
Biological pathway: the set of linked biological components and their mutual interactions over time that generate a 
particular biological e# ect.
Bioequivalence: pharmacokinetic similarity (of drugs) as established statistically.
Compound: a chemical structure comprising identical molecules each of two or more elements.
Drug target: an enzyme, receptor, channel, or other kind of molecule participating in a biological pathway.
Ef cacy: capacity to produce a desired e# ect.
Enzyme: a protein that acts as a catalyst in chemical or biological reactions.
Precedented drug: a drug that seeks to a# ect a well-documented drug target. 
Generic drug: a drug manufactured under license to its patent’s owner or a% er expiry of patent rights on its 
manufacture.
Hit-to-lead: a series of screens imposed during drug discovery that identify the most promising “lead” compounds 
from a larger pool of high-potential “hit” compounds.
Innovation system: the infrastructure, team-building methods, or corporate culture used to facilitate innovation.
In vitro: in the laboratory.
In vivo: in the body.
Lead optimization: widely considered the most challenging stage in the drug development process.  In lead 
optimization, promising “lead” compounds identi$ ed through screening are enhanced through multistage 
re$ nements of their chemical structure to maximize speci$ city within a target drug pathway.  " is process is highly 
iterative and nonlinear.
Microdose: a dose (administered during clinical e!  cacy trials) su!  cient to enable monitoring of pharmacokinetics 
but not drug toxicity or safety.
New-concept drug: a drug that is the $ rst to be designed to take advantage of a drug target.
Parenteral: piercing or bypassing the skin or mucous membrane.
Pharmacokinetics: absorption, distribution, metabolism, and excretion (of a drug).
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Phase IIA Clinical Trials: Clinical trials assessing drug e!  cacy on a small population of human subjects.
Phase IIB Clinical Trials: Clinical trials assessing e!  cacy and dose ranging on large populations of human subjects.
Value chain: the interrelated series of activities that contribute to the production and delivery of a given product or 
service.
Value-chain governance: the series of power and coordination relationships between a $ rm and its suppliers, 
characterized by supplier capabilities, codi$ ability of information, and transaction complexity.
GLOSSARY
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Appendix B: Methodology
Company summaries: Here we use a case-based analysis of pharmaceutical companies located in India and China to 
ascertain how new business strategies and value-sharing relations are allowing $ rms in both countries to contribute 
to international drug-discovery and drug-development projects. We conducted on-site interviews in Shanghai and 
Beijing, in China; and in Bangalore, Delhi, Pune, and Hyderabad, in India.  " ese were supplemented by phone 
interviews.  We sought out sta#  with intimate details of a company’s strategic activities, research and development 
projects, and future vision.  In most cases we interviewed Chief Executive O!  cers, Chairmen, and Vice Presidents.  
During our interviews, we sought to extract data on each company’s business model and relationship with partners; 
research and development activities; personnel training; and recruitment.
Value chains: We analyzed value-chain constraints on the type and complexity of drug discovery and drug 
development, clinical trials, and manufacturing work being assigned to India and China.  Based on established 
academic literature; reports; and our team’s site visits, we structured the breakdown by stages of these value chains 
to most accurately depict the key steps involved in this increasingly fragmented industry.
Intellectual property: In order to track the global locations of recent innovation, our team made use of the World 
Intellectual Property Organization’s (WIPO) Patent Cooperation Treaty (PCT) database.  PCT applications are a 
means of seeking intellectual-property protection in multiple countries simultaneously.  Currently recognized by 
184 member countries, WIPO allows an individual or entity to $ le a single international application to begin the 
patenting process rather than submit individual national or regional patent applications.
Each piece of intellectual property described in a PCT application is accompanied by a group of International 
Patent Classi$ cation (IPC) codes.  " ese codes allow intellectual property to be grouped independent of 
technology areas.  Our team conducted a detailed analysis of IPC codes that classify biological and chemical 
reactions relevant to the pharmaceutical industry; medical equipment; and diagnostic procedures.  By analyzing 
the codes most o% en $ led under by the highest-earning pharmaceutical companies, we were able to identify a 
listing of 379 codes that encompass a representative sample of pharmaceutical $ lings (see Appendix D).  We used 
these to estimate the change in pharmaceutical PCT application $ ling activity from 1995 to 2006.
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Here we present a more detailed version of 
the pharmaceutical value chain (see Figure 6), 
including more-detailed discussions of the activities 
characterizing drug discovery & development, clinical 
trials, and manufacturing activities.
Drug discovery and development is the process 
employed to identify new biological compounds and 
then re$ ne and develop them into a drug candidate.  
" e clinical trials process is the series of tests required 
by most developed markets to demonstrate a drug 
candidate’s safety, e!  cacy, and manufacturability.  
Finally, the manufacturing process depicts the 
high-yield, scalable chemical reactions required to 
mass-produce a drug.  Boxes in this value chain are 
representative of a stage in the process.  Bold text, 
such as “Drug Candidate”, inside a rounded box 
indicates a product.  A detailed explanation of the 
interactions between the stages follows.
Drug discovery and development: New 
pharmaceutical drugs largely fall into one of three 
distinct categories: new-concept drugs, precedented 
drugs, and generics.
A new-concept drug is the $ rst drug product 
designed to take advantage of a particular drug target.  
" ese are the most expensive drugs to develop; in 
many cases, they rely on new lines of research or 
biological-pathway models.  New-concept drugs 
represent a minority of all drugs in development 
and are usually developed by large international 
pharmaceutical corporations with substantial R&D 
experiences and resources and technically pro$ cient 
personnel.
" e majority of drugs actively in development can 
be classi$ ed as potential precedented drugs.  " ese 
potential drugs rely on scientists’ knowledge of a 
documented drug target and the related functionality 
of existing drugs.  Precedented drugs o% en compete 
with a preexisting drug on the market or are 
intended to provide incremental improvements or 
di# erentiation.
Drug discovery and development for new-concept 
and precedented drugs is a complicated and iterative 
process.  " e $ rst step is the identi$ cation of a 
drug target. " is usually involves locating a speci$ c 
Appendix C: Detailed pharmaceutical value chain
Figure 6:
The detailed pharmaceutical value chain
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biological process related to a disease.  Identifying 
this series allows researchers to predict means of 
emulating, disrupting, limiting, or otherwise a# ecting 
the drug target.  In the biological identi! cation stage, 
researchers identify a speci$ c molecule, generally a 
large protein or enzyme that plays a role critical to 
disease progression.
Future drug-development e# orts will aim to 
minimize, redirect, nullify, or reproduce the e# ects 
of this molecule in order to alter the expression of 
the disease, invoke immune responses, or counter 
the results of another biological process.  To 
accomplish this, researchers engage in compound 
generation, a process in which a multitude of 
biological compounds is collected from amongst 
natural products, genetically produced compounds, 
chemically synthesized compounds, and the contents 
of compound libraries.
" rough a detailed compound-screening process, 
the most promising compounds are identi$ ed: 
those that have the largest e# ect on the drug target.  
Multiple, increasingly scrupulous screens (“hits-
to-leads”) highlight the compounds with strongest 
potential e# ect.
" is stage is followed by lead optimization, widely 
considered the most challenging in the development 
process.  In lead optimization, promising “lead” 
compounds identi$ ed through screening are 
enhanced through multistage re$ nements of their 
chemical structure to maximize speci$ city to a drug 
target.  " is process is highly iterative and nonlinear.
Optimized compounds are validated through a 
series of chemical and laboratory tests to con$ rm that 
their re$ nements have not reduced their desired e# ect 
on the drug target .
Before clinical trials can begin, the FDA requires 
evidence that a drug meets basic safety standards.  
Preclinical development, in the form of successful 
in-vitro laboratory or animal studies, can be used 
to validate a drug’s toxicity and pharmacological 
e# ects to satisfy these requirements.  Ultimately a 
drug candidate is produced that, accompanied by 
a Chemistry, Manufacturing, and Controls (CMC) 
documentation package, can enter clinical trials.
Finally, the manufacture of generic drugs relies on 
publicly available intellectual property documenting 
existing biological compounds that no longer 
qualify for patent protection.  Generics markets vary 
signi$ cantly internationally, entailing specialized 
e# orts to abide by national laws that govern generics’ 
distribution and sale.
Clinical trials: " e FDA requires that a series 
of demanding clinical trials demonstrate a drug 
candidate’s toxicology, e!  cacy, and speci$ city in 
order to test its conformity to standards of safety 
and e# ectiveness.  Before clinical trials begin, three 
parallel streams of preclinical testing must occur.
Laboratory and animal testing is completed to 
determine whether the candidate drug appears to 
meet basic safety and e!  cacy requirements.
Pharmacokinetic analysis is conducted to gauge a 
drug candidate’s absorption, distribution, metabolism, 
and excretion.  Absorption and distribution testing 
determines the amount of compound that is actually 
assimilated into and incorporated by the biological 
system.  " e biological pathway and the results 
of absorption and distribution testing determine 
whether a substance will be administered orally, 
topically, or parenterally.  Metabolism and excretion 
testing ascertains how a drug candidate is functionally 
processed or modi$ ed by the biological system it is 
introduced to.  Blood, urine, and feces are analyzed at 
regular intervals in order to gauge drug metabolism.  
Finally, preclinical manufacturing and chemistry tests 
determine whether a drug candidate can be produced 
in large quantities in a time- and cost-e# ective 
manner.
" e completion of preclinical testing is 
accompanied by the $ ling of an Investigational 
New Drug (IND) Application with the FDA.  " is 
application, which documents the compound’s 
chemical structure, $ ndings of prior testing, and 
manufacturability, is approved by default unless the 
FDA $ nds fault with the documentation within thirty 
days of $ ling.
Following IND approval, a rigorous series of clinical 
trials begins.  " roughout this process, status reports 
are regularly sent to the FDA.  Recently created, phase 
DETAILED PHARMACEUTICAL VALUE CHAIN
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0 clinical trials are brief exploratory trials limited in 
duration to seven days or less, in which microdoses of 
a drug candidate are delivered to human test subjects 
in order to monitor its pharmacokinetics.  " e trials’ 
main purpose is to exclude poorly performing drugs 
from the time- and cost-intensive clinical trials that 
would otherwise follow.
As noted earlier, phase I clinical trials are generally 
conducted on a small body of healthy volunteers to 
test a drug candidate’s safety and pharmacokinetics 
in human test subjects.  " ey are followed by phase 
II clinical trials, designed to assess drug functionality 
and build upon safety $ ndings obtained from 
phase I trials.  Phase II trials are conducted on 
larger patient groups and gather information on 
the e!  cacy and safety of various dosages.  Phase III 
trials o% en represent a bottleneck in clinical-trial 
development, being the most costly, time-intensive, 
and complex.  " ey involve large patient groups, 
consisting of hundreds or thousands of volunteers, 
depending on the target condition.  " e trials must be 
carefully designed and expertly executed if they are to 
e# ectively demonstrate drug safety and e!  cacy and 
ultimately obtain regulatory approval.
Upon completion of phase III clinical trials, 
a New Drug Application (NDA) is $ led.  NDA 
documentation must contain all of the scienti$ c 
information collected in a drug’s development: all 
safety, e!  cacy, toxicology, and pharmacokinetic 
analysis; results from clinical and preclinical analysis; 
documentation of the drug’s chemical structure; and 
all patent information. In some cases, NDAs can 
run to more than one hundred thousand pages in 
length.  Following NDA submission, drug approval 
for commercial distribution is granted by the FDA.  
Phase IV clinical trials track a drug for long-term 
safety e# ects a% er FDA approval has been granted for 
the drug’s commercial sale.  " is safety monitoring 
is in place to identify any potential long-term safety 
or toxicology concerns that did not arise during the 
previous trials.
" e approval of generic drugs is far less time-
intensive and clinically rigorous.  Approval of an 
identi$ ed o# -patent drug or compound requires $ ling 
of an Abbreviated New Drug Application (ANDA).  
ANDAs generally do not require a demonstration 
of safety, toxicology, or pharmacokinetics.  Nor do 
they require the completion of the aforementioned 
clinical-trial procedures; these requirements are 
deemed to have been documented in prior NDAs 
when the target extant drug or compound was 
originally conceived.  Instead, ANDAs require 
the documentation of bioequivalence.  " e 
documentation of their bioequivalence testing must 
show that a generic drug’s performance is similar 
to that of its original drug predecessor.  Given an 
acceptable bioequivalence pro$ le, a generic drug will 
be approved for mass production.
Manufacturing: To deliver a potential drug from 
a laboratory or small-scale testing environment 
to national or international patient populations 
requires reliable control of chemical reactions 
and manufacturing dynamics.  To mass-produce 
a drug, raw materials are combined through 
high-yield drug-production reactions.  Identifying 
scalable, simple, cost-e# ective chemical reactions 
by which to produce large quantities of a target 
drug is essential.  " ese reactions produce drug 
intermediates, active pharmaceutical ingredients, 
and pharmacological products that are the building 
blocks of $ nalized drugs.  Some pharmaceutical 
manufacturing companies mass-produce these 
intermediate components for consumption by other 
pharmaceutical entities.  " rough further processing 
and additional chemical reactions, a $ nal drug 
product emerges for distribution.
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Appendix D: International Patent Classi cation (IPC) 
codes used in our WIPO PCT analysis
C08F 220/
C08F 290/
C08F 299/
C08F 4/
C08F 8/
C08G 18/
C08G 59/
C08G 61/
C08G 63/
C08G 65/
C08G 69/
C08G 73/
C08G 75/
C08G 77/
C08J 3/
C08J 5/
C08J 7/
C08K 3/
C08K 5/
C08K 9/
C08L 101/
C08L 23/
C08L 3/
C08L 33/
C08L 5/
C08L 63/
C08L 67/
C08L 71/
C08L 83/
C09C 1/
C09C 3/
C11B 1/
C11C 3/
C12M 3/
C12M 1/
C12N 11/
C12N 15/
C12N 1/
C12N 15/
C12N 5/
C12N 7/
C12N 9/
C12P 1/
C12P 11/
C12P 15/
C12P 23/
C12P 25/
C12P 27/
C12P 29/
C12P 3/
C12P 31/
C12P 33/
C12P 35/
C12P 37/
C12P 39/
C12P 9/
C12P 13/
C12P 17/
C12P 19/
C12P 21/
C12P 41/
C12P 7/
C12Q 1/
C12R 1/
C40B 60/
G01F 1/
G01F 11/
G01F 25/
G01N 24/
G01N 1/
G01N 15/
G01N 21/
G01N 27/
G01N 30/
G01N 31/
G01N 33/
G01N 35/
H01J 49/
H04R 29/
